Formulari Ubat ubatan kkm

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY N06DA03123C1003 should be reinitiated at the1367 Rivastigmine 4.5 mg XX For psychiatrists and lowest daily dose Capsule neurologists only. Mild to Initial dose 1.5 mg 2 times N06DA03123M7001 A* moderately severe dementia daily, may increase by 1.5 XX associated with Alzheimer's mg 2 times daily every 2 or Parkinson's disease weeks to maximum of 6 mg 2 N06DA03123C1004 times daily. If treatment is Rivastigmine 4.6mg/24hr XX Mild to moderately severe interrupted for several days, Transdermal Patch dementia associated with should be reinitiated at the1368 N06DA03123M7002 A* Alzheimer's or Parkinson's lowest daily dose XX Initial, 4.6 mg/24 hr patch disease TOPICALLY once daily; after N03DA03123M7003 a minimum of 4 weeks and1369 Rivastigmine 6 mg Capsule XX For psychiatrists and good tolerability, increase the neurologists only. Mild to dose to 9.5 mg/24 hr patch A* moderately severe dementia once daily associated with Alzheimer's Initial dose 1.5 mg 2 times or Parkinson's disease daily, may increase by 1.5 mg 2 times daily every 2 Rivastigmine 9.5 mg/24hr Mild to moderately severe weeks to maximum of 6 mg 2 Transdermal Patch dementia associated with times daily. If treatment is1370 A* Alzheimer's or Parkinson's interrupted for several days, should be reinitiated at the disease lowest daily dose Initial, 4.6 mg/24 hr patch1371 Rivastigmine Transdermal i) Mild to moderately severe TOPICALLY once daily; after Patch 13.3mg/24 hours dementia associated with a minimum of 4 weeks and Alzheimer's or Parkinson's good tolerability, increase the disease. dose to 9.5 mg/24 hour patch ii) Severe dementia of the once daily Alzheimer's type: - Patient with mild to moderately Initial, 4.6mg/24 hours patch severe dementia (currently TOPICALLY once daily, after A* on lower strength of a minimum of 4 weeks of rivastigmine patch) and treatment and if well developed to severe tolerated, this increased to dementia. - Use as second 9.5mg/24 hours or 13.3mg/24 line/alternative option if the hours (individual responses to rivastigmine may vary and first line medication with oral some patients may derive tablet failed or patients are additional benefit from higher not able to tolerate the oral doses) medication.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 251 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE M03AC09320P3001 CATEGORY1372 Rocuronium Bromide 10 As an adjunct to general Adult: Initially, 600 mcg/kg by mg/ml Injection XX A* anaesthesia to facilitate inj. Higher doses of 1 mg/kg N04BC04110T5003X endotracheal intubation, to may be used for intubation1373 Ropinirole HCI 2 mg A* provide skeletal muscle during rapid sequence Extended Release Tablet X relaxation during surgery and induction of anaesthesia. to facilitate mechanical Maintenance: 150 mcg/kg by ventilation in adults, children inj (may reduce to 75-100 and infants from 3 months of mcg/kg if inhalational age anaesthesia is used) or by infusion at a rate of 300-600 Treatment of idiopathic mcg/kg/hr. Doses should be Parkinson?s disease. It may based on lean body weight be used as monotherapy or for obese patients weighing in combination with levodopa >30% above the ideal body weight. Child: Infants and children >1 mth: Initially, 600 mcg/kg by inj. Maintenance: 150 mcg/kg by inj or by infusion at a rate of 300-600 mcg/kg/hr, maintenance doses may be required more frequently than in adult patients. Elderly: Reduced maintenance doses: 75-100 mcg/kg. Renal impairment: Initially, 600 mcg/kg by inj. Maintenance: 75-100 mcg/kg. Hepatic impairment: or biliary tract disease: Initially, 600 mcg/kg by inj. Maintenance: 75-100 mcg/kg. ADULT: Initially 2 mg once daily for the 1st week. May be increased by 2 mg at ≥1 week intervals. Max: 24 mg/day. Switching from ropinirole immediate- realease to prolonged- release tablet; dose of ropinirole prolonged release tablet should be based on the total daily dose of ropinirole immediate-release tab the patient was taking. Tablets should be taken at a similar time each day with or without food, must be swallowed whole and must not be chewed, crushed or divided.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 252 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1374 Ropinirole HCI 4 mg N04BC04110T5004X Treatment of idiopathic ADULT: Initially 2 mg once Extended Release Tablet X A* Parkinson?s disease. It may daily for the 1st week. May be used as monotherapy or be increased by 2 mg at ≥11375 Ropinirole HCl 0.25 mg N04BCO4110T1001 A* in combination with levodopa week intervals. Max: 24 Tablet XX A* mg/day. Switching from Parkinson disease in younger ropinirole immediate-1376 Ropinirole HCl 1 mg Tablet N04BCO4110T1002 A* patients and patients with realease to prolonged- XX dyskinesias, especially peak release tablet; dose of1377 Ropivacaine HCl 2 mg/ml A* dose dyskinesias ropinirole prolonged release Injection N01BB09110P3001X Parkinson disease in younger tablet should be based on the X patients and patients with total daily dose of ropinirole1378 Ropivacaine HCl 7.5 mg/ml dyskinesias, especially peak immediate-release tab the Injection N01BB09110P3002X dose dyskinesias patient was taking. Tablets X should be taken at a similar i) Surgical anaesthaesia time each day with or without including obstetrics food, must be swallowed ii) Acute pain management whole and must not be chewed, crushed or divided. i) Surgical anaesthaesia including obstetrics 0.25 mg 3 times daily ii) Acute pain management gradually increasing till adequate response obtained up to a maximum of 24 mg/day. Most patients need 3-9 mg/day 0.25 mg 3 times daily gradually increasing till adequate response obtained up to a maximum of 24 mg/day. Most patients need 3-9 mg/day Dose adjusted according to patient physical status and nature of procedure. i) Lumbar epidural: 15-25 ml of 7.5 mg/ml solution; Caesarean section, 15-20 ml of 7.5 mg/ml solution in incremental doses (max. total dose 150 mg). ii) Lumbar epidural: 10-20 ml of 2mg/ml solution followed by 10-15 ml of 2 mg/ml solution at interval at of least 30 minutes. Labour pain 6-10 ml/hour of 2mg/ml solution Dose adjusted according to patient physical status and nature of procedure. i) Lumbar epidural: 15-25 ml of 7.5 mg/ml solution; Caesarean section, 15-20 ml of 7.5 mg/ml solution in incremental doses ( max . total dose 150 mg). ii) lumbar epidural: 10-20 ml of 2mg/ml solution followed by 10-15 ml of 2 mg/mlUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 253 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE1379 Rosiglitazone 4 mg Tablet A10BG02000T1002X CATEGORY solution at interval at of least1380 Rosuvastatin 10 mg Tablet Type 2 diabetes with insulin 30 minutes. Labour pain 6-10 X A* resistant features. Prescribed ml/hour of 2mg/ml solution C10AA07390T1002X to new patients only if A* inadequate glycaemic control 4 mg once daily or in 2 X with all other combination of divided doses, may be oral antidiabetic medications increased to 8 mg/day in 1-2 (such as sulphonylureas, divided doses after 12 week metformin, acarbose or DPPIV inhibitors) and is the Initially 5-10 mg once daily only suitable alternative. Use (5mg in patients with pre- of rosiglitazone in disposing factors to combination with insulin (for myopathy), increased if new patients) is not necessary at intervals of at recommended. Combined least 4 weeks to 20 mg once use with insulin should be daily, increased after further limited to existing cases with 4 weeks to 40 mg daily stable glycaemic control and ONLY in severe requires close monitoring in hypercholesterolemia with view of increased risk of fluid high cardiovascular risk. retention, weight gain and Patient of Asian origin, hypoglycaemia. In cases of patients on concomitant existing use in patients with ciclosporin/fibrate and optimal glycaemic control, patients with risk factors for rosiglitazone should be myopathy/rhabdomyolysis continued with close (including personal/family monitoring of cardiovascular, history of muscular osteoporosis and fracture disorders/toxicity), the risk. maximum dose should be 20 mg daily Dyslipidaemia not responsive to atorvastatin 40 mg or equivalent doses of other statinsUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 254 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Initially 5-10 mg once daily (5mg in patients with pre- disposing factors to myopathy), increased if necessary at intervals of at least 4 weeks to 20 mg once daily, increased after further 4 weeks to 40 mg daily ONLY in severe1381 Rosuvastatin 20 mg Tablet C10AA07390T1003X A* Dyslipidaemia not responsive hypercholesterolemia with X to atorvastatin 40 mg or high cardiovascular risk. equivalent doses of other Patient of Asian origin, statins patients on concomitant ciclosporin/fibrate and patients with risk factors for myopathy/rhabdomyolysis (including personal/family history of muscular disorders/toxicity), the maximum dose should be 20 mg daily A single daily dose should be initiated at 4mg/24 h and1382 Rotigotine 2 mg per 24 hour N04BC09000M7001 A* For stage IV Parkinson then increased in weekly Transdermal Patch XX Disease with peak dyskinesia increments of 2mg/24 h to an effective dose up to a maximal dose of 16mg/24 hr. A single daily dose should be initiated at 4mg/24 h and1383 Rotigotine 4 mg per 24 hour N04BC09000M7002 A* For stage IV Parkinson then increased in weekly Transdermal Patch XX Disease with peak dyskinesia increments of 2mg/24 h to an effective dose up to a maximal dose of 16mg/24 hr. A single daily dose should be initiated at 4mg/24 h and1384 Rotigotine 6 mg per 24 hour N04BC09000M7003 A* For stage IV Parkinson then increased in weekly Transdermal Patch XX Disease with peak dyskinesia increments of 2mg/24 h to an effective dose up to a maximal dose of 16mg/24 hr. A single daily dose should be initiated at 4mg/24 h and1385 Rotigotine 8 mg per 24 hour N04BC09000M7004 A* For stage IV Parkinson then increased in weekly Transdermal Patch XX Disease with peak dyskinesia increments of 2mg/24 h to an effective dose up to a maximal dose of 16mg/24 hr.1386 Rubella Virus Vaccine J07BJ01000P3001X C Immunization against rubella 0.5 ml SC as a a single dose Injection (Single injection) X (German measles) For the treatment of disease- The recommended starting related splenomegaly or dose is 15 mg twice daily for symptoms in adult patients patients with a platelet count with primary myelofibrosis between 100,000/mm3 and L01XE18162T1002X (also known as chronic 200,000/mm3 and 20 mg1387 Ruxolitinib 15mg tablet X A* idiopathic myelofibrosis), twice daily for patients with a post-polycythemia vera platelet count of myelofibrosis or post- >200,000/mm3. There is essential thrombocythemia limited information to myelofibrosis. Place in recommend a starting doseUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 255 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY therapy: To be used as 3rd for patients with platelet line after hydroxyurea and counts between 50,000/mm3 other best available and <100,000/mm3. The treatment such as danazol maximum recommended and S.C. Interferon starting dose in these patients is 5 mg twice daily and the patients should be titrated cautiously. The recommended starting dose is 15 mg twice daily for1388 Ruxolitinib 20mg tablet L01XE18162T1003X A* For the treatment of disease- patients with a platelet count X related splenomegaly or between 100,000/mm3 and symptoms in adult patients 200,000/mm3 and 20 mg with primary myelofibrosis twice daily for patients with a (also known as chronic platelet count of idiopathic myelofibrosis), >200,000/mm3. There is post-polycythemia vera limited information to myelofibrosis or post- recommend a starting dose essential thrombocythemia for patients with platelet myelofibrosis. Place in counts between 50,000/mm3 therapy: To be used as 3rd and <100,000/mm3. The line after hydroxyurea and maximum recommended other best available starting dose in these treatment such as danazol patients is 5 mg twice daily and S.C. Interferon and the patients should be titrated cautiously. The recommended starting1389 Ruxolitinib 5mg tablet L01XE18162T1001X A* For the treatment of disease- dose is 15 mg twice daily for X related splenomegaly or patients with a platelet count symptoms in adult patients between 100,000/mm3 and with primary myelofibrosis 200,000/mm3 and 20 mg (also known as chronic twice daily for patients with a idiopathic myelofibrosis), platelet count of post-polycythemia vera >200,000/mm3. There is myelofibrosis or post- limited information to essential thrombocythemia recommend a starting dose myelofibrosis. Place in for patients with platelet therapy: To be used as 3rd counts between 50,000/mm3 line after hydroxyurea and and <100,000/mm3. The other best available maximum recommended treatment such as danazol starting dose in these and S.C. Interferon patients is 5 mg twice daily and the patients should be titrated cautiously. 2 ml may be inhaled up to 41390 Salbutamol 0.5 % Inhalation R03AC02183A3001 B Asthma and other conditions times daily over a period of 3 Solution XX associated with reversible minutes per inhalation (0.5 ml airways obstruction diluted in 2.5 ml of normal saline by inhalation over 5 to 15 minutes) 500 mcg by SC/IM injection 4 Asthma and other conditions hourly or 250 mcg by slow IV. associated with reversible If required, by IV infusion,1391 Salbutamol 0.5 mg/ml R03CC02183P3001 A airways obstruction initially 5 mcg/min adjusted Injection XX according to response and heart rate, usually in the range 3 - 20 mcg/minUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 256 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE R03AC02183A1001 CATEGORY Asthma and other conditions1392 Salbutamol 100 mcg/dose associated with reversible ADULT : 100 - 200 mcg up to Inhalation XX B airways obstruction 3 - 4 times daily. CHILD : 100 R03CC02183T1001 B Asthma and other conditions mcg increased to 200 mcg if1393 Salbutamol 2 mg Tablet B associated with reversible necessary XX B airways obstruction CHILD 2 - 6 years : 1 - 2 mg1394 Salbutamol 2 mg/5 ml R03CC02183L9001X Asthma and other conditions 3 - 4 times daily, 6 - 12 years Syrup A* associated with reversible : 2 mg 3 - 4 times daily. X airways obstruction CHILD over 12 years and1395 Salbutamol 200mcg/dose R03AC02183A2001 A/KK Asthma and other conditions ADULT : 2 - 4 mg 3 - 4 times Inhaler associated with reversible daily XX B airways obstruction CHILD 2 - 6 years : 1 - 2 mg1396 Salbutamol 5 mg/5 ml C 3 - 4 times daily, 6 - 12 years Injection R03CC02183P3002 Prevention of uncomplicated : 2 mg 3 -4 times daily XX premature labour only CHILD: 100 - 200 mcg. Salicylazosulphapyridine Maintenance: 100 - 200 mcg1397 (Sulfasalazine) 500 mg A07EC01000T1001X i) Treatment of inflammatory 2 - 4 times daily. ADULT: 100 X bowel disease of ulcerative - 400 mcg. Maitenance : 100 Tablet colitis and Crohn's disease - 400 mcg 2 - 4 times daily D07XA01952G5001 ii) Rheumatoid arthritis Infusions containing 5 mg in Salicylic Acid 1 - 2% in XX 500ml (10 mcg/ml) at the rate1398 Hydrocortisone 1% Seborrhoeic capitis of 10 - 45 mcg/min increased D01AE12000G1001 Seborrhoeic dermatitis, scalp at intervals of 10 minutes Ointment XX psoriasis and hyperkeratotic until evidence of patient skin conditions response as shown by1399 Salicylic Acid 2 - 10% reduction of strength, Cream frequency or duration of contractions; maintain rate for 1 hour after contractions have stopped, then gradually reduce by 50% every 6 hours i) ADULT, acute attack 1-2 g 4 times daily until remission occurs (if necessary corticosteroids may also be given), reducing to a maintenance dose of 500 mg 4 times daily, CHILD over 2 years, acute attack 40-60 mg/kg daily, maintenance dose 20-30 mg/kg daily ii) ADULT, initially; 0.5-1 g/day, increase weekly to maintenance dose of 2 g/day in 2 divided doses, maximun 3 g/day. CHILD over 6 years, juvenile rheumatoid arthritis: 30-50 mg/kg/day in 2 divided doses up to a maximum of 2 g/day Apply sparingly to affected areas 1-2 times daily Apply sparingly to the affected area 2-3 times dailyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 257 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1400 Salicylic Acid 2 - 10% D01AE12000G5001 C Seborrhoeic dermatitis, Apply sparingly to the Ointment XX scalp, psoriasis and affected area 2-3 times daily hyperkeratotic skin disorders1401 Salicylic Acid 2 % Lotion D01AE12000L6001X B Seborrhoeic dermatitis, Apply sparingly to the X scalp, psoriasis and affected area 2-3 times daily. hyperkeratotic skin conditions Wash with cleanser 2 - 3 times per day Apply daily and protect1402 Salicylic Acid 20% Ointment D01AE12000G5002 C Plantar warts surrounding skin (eg with soft XX paraffin or specially designed plaster) ,may need to continue up to 3 months1403 Salicylic Acid, Starch, Zinc D01AE12952G6001 Apply the paste liberally and Oxide Paste XX C Use as a protective or base carefully to the lesions twice daily1404 Salmeterol 25 mcg and R03AK06989A2102X A* Regular treatment of ADULT and CHILD more Fluticasone Propionate 125 X reversible obstructive airway than 12 years : 1 - 2 puff mcg Inhalation diseases including asthma. twice daily. CHILD over 4 years : 1 puff twice daily Regular treatment of reversible obstructive airway ADULT and CHILD more diseases including asthma in than 12 years : 2 puff twice Salmeterol 25mcg and R03AK06989A2104X A* children, where use of lower daily. CHILD over 4 years : 21405 Fluticasone Propionate X dose of a combination puff twice daily No data on (bronchodilator and inhaled use for children aged under 4 50mcg Inhalation corticosteroids) is years. appropriate. i) Regular treatment of reversible obstructive airways i) ADULT and CHILD more1406 Salmeterol 50 mcg and R03AK06989A2101X A/KK diseases including asthma than 12 years: 1 puff twice Fluticasone Propionate 250 X ii) For the regular treatment daily. mcg Inhalation of chronic obstructive ii) For COPD: Dose is one pulmonary disease (COPD) inhalation 50/250mcg to including chronic bronchitis 50/500mcg twice daily. and emphysema i) Regular treatment of1407 Salmeterol 50 mcg and R03AK06989A2106X A* reversible obstructive airways i) ADULT and CHILD more Fluticasone Propionate 500 X diseases including asthma than 12 years : 1 puff twice mcg Inhalation ii) Chronic obstructive daily pulmonary disease including ii) ADULT 1 puff twice daily chronic bronchitis and emphysema FUKKM restriction: As add- on therapy for patient who Recommended starting dose failed therapy and/or contraindicated/unable to and maintenance dose in tolerate metformin and/or patients with normal renal sulphonylurea. function and mild renal1408 Saxagliptin 2.5 mg Tablet A10BH03000T1001X A/KK i) As add on therapy in type 2 insufficiency (CrCl more than X diabetes patients 50 ml/min) is 5 mg once inadequately controlled on daily. For patients with metformin monotherapy and moderate to severe renal high risk of hypoglycaemia, insufficiency (CrCl less than especially elderly patients or equal to 50 ml/min) dose is with co-morbidities. 2.5 mg once daily ii) As add on therapy in type 2 diabetes patientsUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 258 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Saxagliptin 2.5mg and A10BD10926T1001X inadequately controlled with The recommended starting1409 Metformin HCl 1000mg X A a sulphonylure and dose of in patients who need A/KK intolerant/contraindicated for 5mg of saxagliptin and who Extended-Release Tablet A10BH03000T1002X metformin therapy are not currently treated with1410 Saxagliptin 5 mg Tablet X iii) As add on therapy in type metformin is 5mg 2 diabetes patients saxagliptin/500 mg metformin inadequately controlled on extended-release once daily metformin and sulphonylurea with gradual dose escalation combination therapy to reduce the gastrointestinal iv) In patients with renal side effects due to metformin. failure where metformin In patients treated with contraindicated Not to be metformin, the dose of used in patients with HbA1c should provide metformin at > 8% on single/combination the dose already being taken, OAD, as insulin initiation is or the nearest therapeutically preferred. appropriate dose. Patients who need 2.5mg saxagliptin FUKKM restriction: As add- in combination with on therapy for patient who metformin extended-release failed therapy and/or may be treated with contraindicated/unable to 2.5mg/1000mg. Patients who tolerate metformin and/or need 2.5mg saxagliptin who sulphonylurea. are either metformin naive or  Indicated as an adjunct who require a dose of metformin higher than to diet and exercise to 1000mg should use the improve glycemic individual components. Max control in adults with daily recommended dose is type 2 diabetes mellitus 5mg/2000mg. when treatment with both saxagliptin and 2.5-5mg once daily. Patients metformin is with CrCl < 50ml/min, and appropriate. when coadministered with strong CYP450 3A4/5 FUKKM restriction: As add- inhibitors: 2.5mg OD on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea. i) As add on therapy in type 2 diabetes patients inadequately controlled on metformin monotherapy and high risk of hypoglycaemia, especially elderly patientsUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 259 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Saxagliptin 5mg and A10BD10926T1002X with co-morbidities. The recommended starting1411 Metformin HCl 1000mg X A ii) As add on therapy in type dose of in patients who need A 2 diabetes patients 5mg of saxagliptin and who Extended-Release Tablet A10BD10926T1003X inadequately controlled with are not currently treated with X a sulphonylure and metformin is 5mg Saxagliptin 5mg and intolerant/contraindicated for saxagliptin/500 mg metformin1412 Metformin HCl 500 mg metformin therapy extended-release once daily iii) As add on therapy in type with gradual dose escalation Extended-Release Tablet 2 diabetes patients to reduce the gastrointestinal inadequately controlled on side effects due to metformin. metformin and sulphonylurea In patients treated with combination therapy metformin, the dose of iv) In patients with renal should provide metformin at failure where metformin the dose already being taken, contraindicated Not to be or the nearest therapeutically used in patients with HbA1c appropriate dose. Patients > 8% on single/combination who need 2.5mg saxagliptin OAD, as insulin initiation is in combination with preferred. metformin extended-release may be treated with FUKKM restriction: As add- 2.5mg/1000mg. Patients who on therapy for patient who need 2.5mg saxagliptin who failed therapy and/or are either metformin naive or contraindicated/unable to who require a dose of tolerate metformin and/or metformin higher than sulphonylurea. 1000mg should use the  Indicated as an adjunct individual components. Max daily recommended dose is to diet and exercise to 5mg/2000mg. improve glycemic The recommended starting control in adults with dose of in patients who need type 2 diabetes mellitus 5mg of saxagliptin and who when treatment with are not currently treated with both saxagliptin and metformin is 5mg metformin is saxagliptin/500 mg metformin appropriate. extended-release once daily with gradual dose escalation FUKKM restriction: As add- to reduce the gastrointestinal on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea.  Indicated as an adjunct to diet and exercise to improve glycemicUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 260 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY control in adults with side effects due to metformin. type 2 diabetes mellitus In patients treated with when treatment with metformin, the dose of both saxagliptin and should provide metformin at metformin is the dose already being taken, appropriate. or the nearest therapeutically appropriate dose. Patients who need 2.5mg saxagliptin in combination with metformin extended-release may be treated with 2.5mg/1000mg. Patients who need 2.5mg saxagliptin who are either metformin naive or who require a dose of metformin higher than 1000mg should use the individual components. Max daily recommended dose is 5mg/2000mg. For treatment of shock due to burns, crushing injuries, abdominal emergencies and1413 Selected Plasma Protein 5 B05AA02000P3001X B where there is a predominant ADULT 12.5-25 g (250-500 g/100 ml Injection X loss of plasma fluids and red ml) by IV. CHILD usual dose blood cells, emergency 33 ml/kg body weight at rate treatment of shock due to of 5-10 ml/min haemorrhage and in infants and small children in the initial therapy of shock due to dehydration and infection1414 Selegiline HCl 5 mg Tablet N04BD01110T1001X A* Only for treatment of late 5 mg twice daily at breakfast X stage Parkinsonism with on and lunch. Maximum 10 and off phenomenon mg/day Dandruff: apply 5-10 mL topically twice weekly for 2 weeks, then 1-4 times per month, as needed, leave on Dandruff, seborrheic for 2-3 min, then rinse Selenium Sulphide 2.5% D11AC03180L5201X dermatitis of scalp thoroughly. Seborrheic1415 Shampoo X A/KK dermatitis of scalp: apply 5- 10 mL topically twice weekly for 2 weeks, then 1-4 times per month, as needed, leave on for 2-3 min, then rinse thoroughly Depression, obsessive- compulsive disorder: 50 mg/day, may increase in1416 Sertraline HCI 50 mg Tablet N06AB06110T1001X B Major depression, obsessive- steps of 50mg at weekly X compulsive disorder (OCD), interval, max: 200mg/day. panic disorder Panic disorder: Initially 25 mg/day. After 1 week, increase dose to 50 mg/day. All dose changes should be made at intervals of moreUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 261 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY than 1 week, max: 200 mg/day1417 Sevelamer 800mg Tablet V03AE02121T1001X A* Control of Starting dose is one or two X hyperphosphatemia in adult 800mg tablets three times patients receiving per day with meals. Adjust by1418 Sevoflurane Liquid N01AB08000L5001X A* haemodialysis and peritoneal one tablet per meal in two X dialysis. Restriction: weeks interval as needed to Sevelamer carbonate 800mg obtain serum phosphorus1419 Sildenafil Citrate 20 mg G04BE03136T1004X A* tablet should be used in target (1.13 to 1.78mmol/L). Film-coated Tablet X context of multiple therapeutic approach which i) Adult: Given via a include calcium supplement, calibrated vaporiser: Up to 1, 25-hydroxy Vitamin D3 or 5% v/v with oxygen or a one of its analogues to mixture of oxygen and nitrous control the development of oxide. Child: Given via a renal bone disease. calibrated vaporiser: Up to 7% v/v. To be used only for ii) Adult: 0.5-3% v/v with or i) induction and without nitrous oxide. Child: ii) maintenance of 0.5-3% v/v with or without anaesthesia nitrous oxide. ADULTS ≥ 18 years: The Treatment of adult patients recommended dose is 20mg with pulmonary arterial three times a day. Tablets hypertension classified as should be taken WHO functional class II and approximately 6 to 8 hours III, to improve exercise apart with or without food. capacity. Efficacy has been ELDERLY (≥65 years): shown in primary pulmonary Dosage adjustments are not hypertension and pulmonary required in elderly patients. hypertension associated with Clinical efficacy as measured connective tissue disease. by 6-minute walk distance could be less in elderly patients. IMPAIRED RENAL FUNCTION: Initial dose adjustments are not required in patients with renal impairment, including severe renal impairment (creatinine clearance <30ml/min). A downward dose adjustment to 20 mg twice daily should be considered after a careful benefit-risk assessment only if therapy is not well- tolerated.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 262 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY IMPAIRED HEPATIC1420 Silver Nitrate 0.5% Lotion D08AL01221L6001X Use as antiseptic FUNCTION: Initial dose X B adjustments are not required1421 Silver Sulfadiazine 1% B Prevention and treatment of in patients with hepatic Cream D06BA01199G1001 B infections in severe burns, impairment (Child-Pugh class XX B leg ulcers where infections A and B). A downward dose1422 Simvastatin 10 mg Tablet B may prevent healing and for adjustment to 20mg twice1423 Simvastatin 20 mg Tablet C10AA01000T1001X the prophylaxis of infections daily should be considered1424 Simvastatin 40 mg Tablet X A* in skin grafting after a careful benefit-risk Hypercholesterolaemia and assessment only if therapy is1425 Sitagliptin 100 mg Tablet C10AA01000T1002X A* coronary heart disease not well-tolerated. X intolerant or not responsive Apply undiluted to affected1426 Sitagliptin 25 mg Tablet to other forms of therapy area for a limited period C10AA01000T1003X Hypercholesterolaemia and Burns: Apply 3 mm thick X coronary heart disease layer twice daily with sterile intolerant or not responsive applicator. Leg ulcer: apply at A10BH01000T1003X to other forms of therapy least 3 times a week X Hypercholesterolaemia and coronary heart disease 10 - 20 mg once daily. A10BH01000T1001X intolerant or not responsive Maximum: 80 mg daily X to other forms of therapy FUKKM Restriction: As 10 - 20 mg once daily. add-on therapy for patient Maximum: 80 mg daily who failed therapy and/or contraindicated/unable to 10 - 20 mg once daily. tolerate metformin and/or Maximum: 80 mg daily sulphonylurea.  Management of ADULT over 18 years, 100 mg once daily: 100mg once diabetes in patients with daily CrCl ≥ 30 to < renal failure where 50ml/min: 50mg once daily metformin/sulphonylurea CrCl < 30 ml/min: 25mg once is daily contraindicated/untolerat ed and elderly with ADULT over 18 years, 100 multiple co-morbidities mg once daily: 100mg once that always experience daily CrCl ≥ 30 to < hypoglycemia with other 50ml/min: 50mg once daily antidiabetic. CrCl < 30 ml/min: 25mg once Not to be used in diabetic daily patient whose HbA1c is more than 9%. FUKKM restriction: As add- on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 263 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Sitagliptin 50 mg and A10BD07926T1003X  Management of 50 mg/500 mg twice daily.1427 Metformin HCl 1000 mg X A* diabetes in patients with The recommended maximum renal failure where daily dose is 100 mg Tablet A10BD07926T1001X A* metformin/sulphonylurea sitagliptin plus 2000 mg X is metformin Sitagliptin 50 mg and contraindicated/untolerat1428 Metformin HCl 500 mg ed and elderly with 50 mg/500 mg twice daily. multiple co morbidities The recommended maximum Tablet that always experience daily dose is 100 mg hypoglycemia with other sitagliptin plus 2000 mg antidiabetic. metformin Not to be used in diabetic patient whose HbA1c is more than 9% FUKKM restriction: As add- on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea. i) Type 2 diabetes patients, especially the elderly, with multiple co-morbidities that always experience hypoglycaemia with other antidiabetics who are inadequately controlled on metformin or sitagliptin alone or already being treated with the combination of sitagliptin and metformin. ii) Newly diagnosed type 2 diabetes patients with high baseline HbA1c and multiple co-morbidities who may experience hypoglycaemia with other antidiabetics. FUKKM restriction: As add- on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea. i) Type 2 diabetes patients, especially the elderly, with multiple co-morbidities that always experience hypoglycaemia with other antidiabetics who are inadequately controlled on metformin or sitagliptin alone or already being treated with the combination of sitagliptin and metformin. ii) Newly diagnosed type 2 diabetes patients with high baseline HbA1c and multipleUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 264 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY co-morbidities who may experience hypoglycaemia with other antidiabetics. FUKKM restriction: As add- on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea. i) Type 2 diabetes patients, especially the elderly, with multiple co-morbidities that always experience 50 mg/500 mg twice daily. Sitagliptin 50 mg and A10BD07926T1002X A* hypoglycaemia with other The recommended maximum1429 Metformin HCl 850 mg X antidiabetics who are daily dose is 100 mg inadequately controlled on sitagliptin plus 2000 mg Tablet metformin or sitagliptin alone metformin or already being treated with the combination of sitagliptin and metformin. ii) Newly diagnosed type 2 diabetes patients with high baseline HbA1c and multiple co-morbidities who may experience hypoglycaemia with other antidiabetics. FUKKM restriction: As add- on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea. - Management of diabetes in ADULT over 18 years, 100 patients with renal failure mg once daily: 100mg once1430 Sitagliptin 50 mg Tablet A10BH01000T1002X A* where daily CrCl ≥ 30 to < X metformin/sulphonylurea is 50ml/min: 50mg once daily contraindicated/untolerated CrCl < 30 ml/min: 25mg once and elderly with multiple co daily morbidities that always experience hypoglycemia with other antidiabetic. Not to be used in diabetic patient whose HbA1c is more than 9%.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 265 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Treatment of symptoms of gastro-oesophageal reflux Sodium Alginate 1000 eg. acid regurgitation, heartburn, indigestion due to1431 mg/10 ml & Potassium A02BX13915L8001X A* the reflux of stomach Adult, elderly & children ≥12 Bicarbonate 200 mg/10 ml X contents not responding to year: 5-10 mL. Suspension conventional antacids or as an addition to PPI when PPI alone fails to control the symptoms Depend on the type of1432 Sodium and Meglumine V08AA01993P3002X B For IV pyelography procedure and the degree Diatrizoate 58-60% Injection X and extent of contrast required1433 Sodium Bicarbonate 1 g/15 A02AH00131L2102X B i) Relief of discomfort in mild i) 3 g in every 2 hours until ml Mixture X urinary tract urinary pH exceeds 7 ii) Alkalinisation of urine ii) Maintenance of alkaline urine 5-10 g daily For acceleration of excretion Sodium Bicarbonate 4.2% B05XA02131P3001X in drug intoxication (where IV infusion of 2 - 5 mmol/kg (0.5 mmol/ml) Injection X excretion of the drug into the body weight over a period of1434 B urine is accelerated by 4 - 8 hours or according to elevated urine pH) and for the needs of the patients acidosis1435 Sodium Bicarbonate 5% w/v S02DC00131D1001 C To soften the impacted ear 2-3 drops 3-4 times daily Ear Drops XX wax For acceleration of excretion1436 Sodium Bicarbonate 8.4% B05XA02131P3002X B in drug intoxication (where According to the needs of the (1 mmol/ml) Injection X excretion of the drug into the patient. In severe shock due urine is accelerated by to cardiac arrest: 50 ml by IV elevated urine pH) and for acidosis1437 Sodium Bicarbonate A02AH00131L2101X C Heartburn for rapid relief of CHILD up to 1 year 5 ml; up Mixture (Paediatric) X dyspepsia to 1-5 years 10 ml in 4 to 6 divided doses For relieving of discomfort in mild urinary tract infection, Sodium Bicarbonate, Citric B05CB10955M4001 symptomatic relief of dysuria 4 - 8 g (1- 2 sachets) Acid, Sodium Citrate and XX to enchance the action to dissolved in a glass of cold1438 Tartaric Acid - 4 g per B certain antibiotics especially water 4 times daily as some sulphonamides. In gout prescribed sachet as urinary alkalinizers to prevent cystallisation of urates Sodium Bicarbonate,1439 Magnesium Carbonate, A02AH00912L2101X C Heartburn, for rapid relief of ADULT 10-20 ml 3 times Tincture Cardamom X dyspepsia daily Compound Mixture Bowel cleansing before Sodium Biphosphate 16%, A06AG01162G2001 A colonic surgery, colonoscopy ADULT 133 ml (1 bottle)1440 Sodium Phosphate 6% XX or radiological examination to administered rectally. CHILD ensure the bowel is free of more than 2 years half the Rectal Solution solid contents. It is not to be adult dose (66.6ml) used for treatment of constipationUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 266 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY 45 ml diluted with half a glass (120 mL) of water, followed by one full glass (240 mL) of water. Timing of doses is dependent on the time of the procedure. For morning procedure, first dose should Bowel cleansing before be taken at 7 a.m. and colonic surgery, colonoscopy second at 7 p.m. on day Sodium Biphosphate 16%, A06AG01162L9901X A or radiological examination to before the procedure. For1441 Sodium Phosphate 6% X ensure the bowel is free of afternoon procedure, first solid contents. It is not to be dose should be taken at 7 Solution used for treatment of p.m. on day before and constipation second dose at 7 a.m. on day of the procedure. Solid food should not be taken during the bowel preparation period. However clear fluids or water can be taken liberally. CHILD under 12 years not recommended For replenishing fluid and Sodium Chloride 0.18% B05XA03904P6001X energy and for restoring or According to the needs of the1442 with Dextrose 10% Injection X B maintaining the concentration patient of sodium and chloride ions Sodium Chloride 0.18% B05XA03904P6004X B For replenishing fluid and According to the needs of the1443 with Dextrose 4.23% X patient energy and for restoring or Injection maintaining the concentration of sodium and chloride ions1444 Sodium Chloride 0.45% B05XA03100P6001X B For replenishing fluid and for 100 - 1000 ml by IV or Injection X restoring / maintaining the according to the needs of the concentration of sodium and patient chloride ions Sodium Chloride 0.45% B05XA03904P6002X For replenishing fluid and with Dextrose 10% Injection X energy and for restoring or According to the needs of the1445 B maintaining the concentration patient of sodium and chloride ions For replenishing fluid and1446 Sodium Chloride 0.45% B05XA03904P6005X B energy and for restoring or According to the needs of the with Dextrose 5% Injection X maintaining the concentration patient of sodium and chloride ions1447 Sodium Chloride 0.9% Eye S01XA03000D2001X C Irrigation of conjunctival sac 1 - 2 drops every 3 - 4 hours Drops X1448 Sodium Chloride 0.9% B05XA03100P6002X C+ For replenishing fluid and for 100 - 1000 ml by IV or Injection X restoring/maintaining the according to the needs of the concentration of sodium and patient chloride ions For replenishing fluid and1449 Sodium Chloride 0.9% with B05XA03904P6003X C+ energy and for restoring or According to the needs of the Dextrose 5% Injection X maintaining the concentration patient of sodium and chloride ions Addition of sodium electrolyte in parenteral nutrition bags1450 Sodium Chloride 20% B05XA03100P9902X B especially in paediatrics or According to the needs of the Injection X neonates with restricted fluid patient allowanceUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 267 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE B05XA03100P9901X CATEGORY According to the needs of the1451 Sodium Chloride 3% Acute dilutional patient Injection X B hyponatraemia Usual dose range : 10 - 200 V09GX00143L9901X A* Labelling of erythrocytes for microcuries IV by IV injection1452 Sodium Chromate B the investigation of Dose depending on clinical (Chromium-51) Solution X B haemotological disorders cases. Usually, 30 ml given 10- 60 minutes before1453 Sodium Citrate 0.3 M B05CB02136L9901X B Prophylaxis for aspiration anaesthesia prior to elective Solution X pneumonitis (use as an oral cesarean surgery is an A/KK solution) effective antacid1454 Sodium Citrate 3.8% B05CB02136H3001 C Dose depending on clinical Solution XX Sterile solution for irrigation cases or washout of infected1455 Sodium Citrate, Citric Acid B05CB02136L2101X bladder ADULT 10 - 20 ml. CHILD up Mixture 3 g/10 ml X Citrates and citric acid to 1 year 2.5 ml tds; 1-5 year solutions are used to correct 5 ml tds; 6-12 years 10 ml1456 Sodium Cromoglycate 2% S01GX01520D2001 the acidosis of certain renal tds. To be taken well diluted Eye Drops XX tubular disorders to treat with water metabolic acidosis for long- Sodium V07AV00000T1001X term urine alkalinization for 1 or 2 drops 4 times daily1457 Dichloroisocyanurate 2.5 g X prevention and treatment of uric acid and calcium kidney 50 - 10,000 ppm av chlorine Tablet stones and as nonparticulate neutralizing buffers Sodium Prevention and treatment of1458 Dichloroisocyanurate 5 g allergic conjunctivitis including seasonal and Tablet perennial allergic conjunctivitis and vernal keratoconjunctivitis Low and medium level disinfectant V07AV00000T1002X C Low and medium level 50 - 10,000 ppm av chlorine X disinfectant Skin infections caused by Sodium Fusidate 2% D06AX01520G5001 staphylococci, streptococci, Apply to affected area 2 - 3 Ointment XX corynebacterium times daily1459 A minutissumun and other sodium fusidate-sensitive organisms Adults: The recommended dosage is individual. The recommended daily dosage of phosphate during intravenous nutrition would Indicated in adult patients normally be 10-20mmol. This Sodium glycerophosphate B05XA14171P3001X A and infants as a supplement can be met by using 10-20ml1460 for addition into infusion X in intravenous nutrition to of sodium glycerophosphate meet the requirement of to the infusion solution or to solution, 20ml vial phosphate. the admixture for which compatibility has been proved. Infants: The recommended dosage is individual. The recommended dose for infants andUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 268 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY neonates is 1.0-1.5 mmol/kg bodyweight/day.1461 Sodium Hypochlorite V07AV00000L9903X C Low-level disinfectant and Antiseptic: less than 0.5%. Solution X A* antiseptic Disinfectant: 5% A* Used in the determination of1462 Sodium Iodide (Iodide-131) V09FX03200P3001X A* various thyroid functions 5 - 50 millicuries Injection X Determination of various A* thyroid functions 5 - 10 milicuries (5 mCi for1463 Sodium Iodide (Iodine-131) V09FX03200C1001X whole body scan) Capsule X i) Thyrotoxicosis i) 2 - 30 millicuries ii) Thyroid carcinoma ii) 80 - 300 millicuries1464 Sodium Iodide (Iodine-131) V10XA01200C1001X Capsule (Therapeutic) X1465 Sodium Iodide (Iodine-131) V10XA01200L9901X i) Thyrotoxicosis i) 5-25 millicuries Solution X ii) Thyroid carcinoma ii) 30-150 millicuries1466 Sodium Nitrite 30 mg/ml V03AB08220P3001X B For cyanide poisoning Adult: 300 mg sodium nitrite Injection X IV over 3 minutes followed i) Hypertensive crisis after 5 minutes with 12.5g1467 Sodium Nitroprusside 10 C02DD01520P3001 A ii) Controlled hypotension sodium thiosulphate IV mg/ml Injection XX during anaesthesia in order administered over 10 to reduce bleeding in surgical minutes. CHILD: 4 - 10 procedures mg/kg of sodium nitrite (max: 300 mg) followed by 400 mg/kg of sodium thiosulfate, as a 25 or 50% solution (max: 12.5 g). Methaemoglobin concentration should not exceed 30-40%. If symptoms of cyanide toxicity recur, the doses of nitrite and thiosulfate may be repeated after 30 min at half the initial doses. i) By IV infusion, initially 0.5- 1.5 mcg/kg/min, then adjusted before increasement of 0.5 mcg/kg/min every 5 mins within range 0.5-8 mcg/kg/min (lower doses in patients already receiving other antihypertensives); stop if marked response not obtained with max dose in 10 minutes. Use only in infusion with 5 % Dextrose IV. ii) By IV infusion, max: 1.5 mcg/kg/minUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 269 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE V10XX01162P3001X CATEGORY Polycythemia vera, chronic1468 Sodium Phosphate myeloid and chronic Initially 5 millicuries, follow if (Phosphorus-32) Injection X A* lymphocytic leukaemia and necessary by a dose of not A palliative treatment of bone more than 3 or 4 millicurie at1469 Sodium Polystyrene V03AE01520F2101X metastases intervals of not less than 2 Sulphonate Powder X A* months A* Treatment and prevention of1470 Sodium Tetradecyl C05BB04183P3001X C hyperkalaemia associated ADULT: Oral: 15 g 1 - 4 Sulphate 1 % Injection X with anuria or severe oliguria, times/day. Rectal: 30 g in B in dialysis patients or those 100 ml 2% methylcellulose1471 Sodium Tetradecyl C05BB04183P3002X on prolonged peritoneal and 100 ml water as a daily Sulphate 3 % Injection X dialysis retention enema. Retain for 9 hours followed by non-1472 Sodium Thiosulphate 10- D01AE00181L9901X Sclerotherapy of sodium cleansing enema. 20% Solution X oesophageal varices, CHILD: 1 g/kg in 1 - 4 doses haemorrhoids and varicose in acute hyperkalemia.1473 Sodium Thiosulphate 500 V03AB06181P3001X veins Maintenance : 0.5 g/kg/daily mg/ml Injection X Sclerotherapy of 0.5-2 mL into the submucosal oesophageal varices, layer at the base of the haemorrhoids and varicose oesophageal varix or the veins haemorrhoid; several injections may be given at Fungicides. For the treatment different sites, max. total of pityriasis versicolor injected 10-15 mL of 1% per treatment For cyanide poisoning 0.5-2 mL into the submucosal layer at the base of the oesophageal varix or the haemorrhoid, several injections may be given at different sites, max. total injected 10-15 mL of 1% per treatment Apply to all affected parts of the body and face with a brush after a bath once daily or twice daily or 3 times daily Adult: To be given after 300 mg of sodium nitrite has been admin over 5-20 min: 12.5 g of sodium thiosulfate (50 ml of a 25% solution or 25 ml of a 50% solution) given over 10 min. Methaemoglobin concentration should not exceed 30-40%. If symptoms of cyanide toxicity recur, the doses of nitrite and thiosulfate may be repeated after 30 min at half the initial doses. Child: To be given after 4-10 mg/kg of sodium nitrite (max: 300 mg) has been admin: 400 mg/kg of sodium thiosulfate, as a 25 or 50% solution (max: 12.5 g). Methaemoglobin concentration should not exceed 30-40%. If symptomsUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 270 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY of cyanide toxicity recur, the doses of nitrite and thiosulfate may be repeated after 30 min at half the initial doses. i) Epilepsy: ADULT: Initially 600 mg/day in 2 - 3 divided doses, dose may be increased by 200 mg at 3- day intervals to max 2.5 g/day. Usual maintenance dose: 1-2 g/day (20-30 mg/kg/day). CHILD: More than 20 kg. Initially 400 mg/day with spaced increases until control is achieved (usually 20-30 mg/kg/day), dose may be increased to 35 mg/kg/day. Less than 20 kg 20 mg/kg/day, in severe cases1474 Sodium Valproate 200 mg N03AG01520T1001 B i) Epilepsy the dose may be increased Tablet XX ii) Treatment and prevention provided plasma of mania associated with concentration can be bipolar disorders monitored. ii) Treatment and prevention of mania associated with bipolar disorders: Adults: The recommended initial dose is 1000mg/day. The dose should be increased as rapidly as possible to achieve the lowest therapeutic dose, which produces the desired clinical effects. The recommended maintenance dosage for the treatment of bipolar disorder is between 1000mg and 2000mg daily. In exceptional cases, the dose may be increased to not more than 3000mg daily.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 271 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULT: Initially 600 mg/day; dose may be increased by 200 mg at 3-day intervals to max 2500 mg/day. Usual maintenance dose: 1000- 2000 mg/day (20-30 mg/kg/day). CHILD: More1475 Sodium Valproate 200 mg/5 N03AG01520L9001X B Epilepsy than 20 kg. Initially 400 ml Syrup X mg/day with spaced increases until control is achieved (usually 20-30 mg/kg/day), dose may be increased to 35 mg/kg/day. Less than 20 kg, 20 mg/kg/day. Severe cases: 50 mg/kg daily ADULT and CHILD above 10 years: 10 to 15 mg/kg/day IV, N03AG01520P4001 may increase 5 to 10 Sodium Valproate 400 mg XX mg/kg/week to achieve1476 Injection B Status epilepticus optimal clinical response (Maximum 60 mg/kg/day or less with a therapeutic range of 50 to 100 mcg/mL) Symptomatic treatment of urge incontinence and/or1477 Solifenacin Succinate 5 mg G04BD08000T1001 A* 5mg od. Dose can be Tablet XX increased urinary frequency increased to 10mg if necessary. and urgency as may occur in patients with overactive bladder syndrome. i) Growth failure due to inadequate endogenous1478 Somatropin 10 mg (30IU) H01AC01000P5002 A* growth hormone. i) 0.7-1 mg/m2/day or 0.025- Injection XX ii) Growth failure in girls due 0.035 mg/kg/day SC/IM. to gonadal dysgenesis ii) 1.4 mg/m2/day or 0.045- (Turner syndrome). 0.05 mg/kg/day SC. iii) Growth failure in short iii) 0.035 mg/kg/day or 1 children born small mg/m2/day SC gestational age (SGA) i) Growth failure due to1479 Somatropin 12 mg (36IU) H01AC01000P3002 A* inadequate endogenous i) 0.7-1 mg/m2/day or 0.025- Injection XX growth hormone 0.035 mg/kg/day SC/IM ii) Growth failure in girls due ii) 1.4 mg/m2/day or 0.045- to gonadal dysgenesis 0.05 mg/kg/day SC (Turner syndrome) iii) 0.035 mg/kg/day or 1 iii) Growth failure in short mg/m2/day SC children born small gestational age (SGA) i) Growth failure due to growth hormone insufficiency i) 0.7-1 mg/m2/day or 0.025- ii) Growth failure in girls due 0.035 mg/kg/day SC/IM1480 Somatropin 5mg (15IU) H01AC01000P3004 A* to gonadal dysgenesis ii) 1.4 mg/m2/day or 0.045- Injection XX (Turner syndrome) 0.05 mg/kg/day SC iii) Growth failure in short iii) 0.035 mg/kg/day or 1 children born small mg/m2/day SC gestational age(SGA)Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 272 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Growth failure due to growth hormone insufficiency i) 0.7-1 mg/m2/day or 0.025- ii) Growth failure in girls due 0.035 mg/kg/day SC/IM Somatropin 8 mg (24IU) H01AC01000P3003 to gonadal dysgenesis ii) 1.4 mg/m2/day or 0.045-1481 Injection XX A* (Turner syndrome) 0.05 mg/kg/day SC iii) Growth failure in short iii) 0.035 mg/kg/day or 1 children born small mg/m2/day SC gestational age(SGA) Supraventricular and ventricular arrhythmias Adult: Initially, 80 mg/day as single or in 2 divided doses, increased gradually every 2-3 days. Usual dose: 160-320 mg/day in 2 divided doses.1482 Sotalol HCl 160 mg Tablet C07AA07110T1002X A* Ventricular tachyarrythmias Life-threatening ventricular X arrhythmias Adult: Initially, 80 mg bid, increased gradually every 3 days to 240-320 mg/day in divided doses if needed. Maintenance: 160- 320 mg/day in divided doses. Max: 480-640 mg in divided doses. Supraventricular and ventricular arrhythmias Adult: Initially, 80 mg/day as single or in 2 divided doses, increased gradually every 2-3 days. Usual dose: 160-320 mg/day in 2 divided doses.1483 Sotalol HCl 80 mg Tablet C07AA07110T1001X A* Ventricular tachyarrythmias Life-threatening ventricular X arrhythmias Adult: Initially, 80 mg bid, increased gradually every 3 days to 240-320 mg/day in divided doses if needed. Maintenance: 160- 320 mg/day in divided doses. Max: 480-640 mg in divided doses. Oedema and ascites in ADULT: 100 - 200 mg daily in cirrhosis of the liver, divided doses. Increase to1484 Spironolactone 25 mg C03DA01000T1001X B congestive heart failure 400 mg if required. CHILD: Tablet X initially 3 mg/kg daily in divided doses Infant: 0 - 13 days old: 0.5 mg/kg/dose twice daily. Infant 14 days and older and1485 Stavudine 1 mg/ml Solution J05AF04000L5001X A* HIV infection, in combination weighing less than 30 kg: 1 X with other antiretrovirals mg/kg twice daily; more than 30 kg and <60kg: 30 mg twice daily ADULT more than 60 kg: 40 mg twice daily; less than 601486 Stavudine 30 mg Capsule J05AF04000C1001X A/KK HIV infection, in combination kg: 30 mg twice daily. CHILD X with other antiretrovirals <30kg: 1mg/kg twice daly; >30kg refer to adult dosageUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 273 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Fixed dose triple therapy for Stavudine 30 mg, J05AR07964T1001X treatment of HIV infection in SLN 30: 30-60 kg 1 tablet1487 Lamivudine 150 mg & X A/KK adults once patients have twice daily. SLN 40 ≥60 kg 1 A* been stabilized on the tablet twice daily Nevirapine 200 mg Tablet J05AF04000C1002X A* maintenance regimen of X nevirapine 200 mg twice daily ADULT more than 60 kg: 401488 Stavudine 40 mg Capsule A* and have demonstrated mg twice daily; less than 60 J05AR07964T1002X adequate tolerability to kg: 30 mg twice daily. CHILD Stavudine 40 mg, X B nevirapine <30kg: 1mg/kg twice daly;1489 Lamivudine 150 mg & >30kg refer to adult dosage B01AD01000P4001X A* HIV infection, in combination Nevirapine 200 mg Tablet X A with other antiretrovirals SLN 30: 30-60 kg 1 tablet twice daily. SLN 40 ≥60 kg 11490 Streptokinase 1,500,000 IU J01GA01183P4001X Fixed dose triple therapy for tablet twice daily Injection X treatment of HIV infection in adults once patients have Myocardial infarction:1491 Streptomycin Sulphate 1 g M05BX03000F1001 been stabilized on the 1,500,000 units over 30 - 60 Injection XX maintenance regimen of minutes. Pulmonary nevirapine 200 mg twice daily embolism: 250,000 units by1492 Strontium Ranelate 2 g V07AV00000L9907X and have demonstrated IV infusion over 30 minutes, Granules X adequate tolerability to then 100,000 units every nevirapine hour for up to 12-72 hours Succindialdehyde 11% & with monitoring of clotting1493 Dimethoxytetrahydrofuran Acute myocardial infarction, factors acute pulmonary embolism ADULT: 15 mg/kg daily; max: 3% 1 g daily. Reduce max daily Tuberculosis dose to 500-750 mg in patients >40 yr. As part of an Treatment of intermittent therapy: 25-30 postmenopausal mg/kg/day 2-3 times/wk; osteoporosis to reduce risk of max: 1.5 g/dose. Not >120 g vertebral and hip fractures over the course of treatment when biphosphonates are should be given unless there contraindicated or not are no other treatment tolerated options. Child: 20-40 mg/kg High level disinfection for (max: 1 g) daily or 25-30 endoscopes, mg/kg (max: 1.5 g) 2-3 times ultrasonicprobes, wkly. anaesthesia equipment etc 2 g sachet once daily Immersion time is based on manufacturers recommendationUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 274 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) 2 g twice daily or 1 g 4 times daily for 4-6 weeks or1494 Sucralfate 1 g Tablet A02BX02000T1001X A i) Benign gastric and in resistant cases up to 12 X duodenal ulceration weeks (maximum 8 g daily) ii) Stress ulcer prophylaxis ii) 1 g 6 times daily (maximum 8 g daily). CHILD not recommended 2 mg/kg sugammadex is recommended, if spontaneous recovery has Indicated for reversal of occurred up to at least the neuromuscular blockade reappearance of second induced by rocuronium and twitch tension of the train-of- vecuronium in selective four (T2). 4 mg/kg Sugammadex 100 mg/ml V03AB35000P3001X patient group: obese, elderly, sugammadex is1495 Injection X A* underlying cardiovascular recommended if recovery disease. For pediatric has reached at least 1- 2 population, sugammadex is post-tetanic counts (PTC). recommended for routine For immediate reversal reversal following administration of rocuronium a dose of 16 mg/kg sugammadex is recommended Chloroquine resistant falciparum malaria acute attack Adult: Per tab contains pyrimethamine 25 mg and sulfadoxine 500 mg: 2-3 tabs as a single dose. Do not repeat for at least 7 days. Child: Pyrimethamine 25mg + Treatment of Plasmodium Sulfadoxine 500mg (Tablet): falciparum malaria in patients <2 yr (5-10 kg): 1/2 (half) tab in whom chloroquine as a single dose; 2-5 yr (>10- Sulfadoxine 500 mg and P01BD51981T1001X B resistance is suspected and 20 kg): 1 tab as a single1496 Pyrimethamine 25 mg X malaria prophylaxis for dose; 5-10 yr (< 20-30 kg): 1 travellers to areas where 1/2 (one and half) tab as a Tablet chloroquine-resistant malaria single dose; 10-14 yr (> 30- is endemic 45 kg): 2 tab as a single dose. Do not repeat for at least 7 days. Renal impairment: Dose reduction may be needed. Severe: contra-indicated. Hepatic impairment: Dose reduction may be needed. Severe: contra-indicated. Mild to moderate infections: more than 2months: 8 - 12mg Sulphamethoxazole 200 mg Trimethoprim/kg/day divided1497 & Trimethoprim 40 mg/5ml J01EE01961L8001X B Infections caused by every 12hours. Serious Suspension X susceptible pathogens Infections: 15-20mg Trimethoprim/kg/day divided every 6hours.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 275 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) ADULT: 960 mg twice daily increased to 1.44 g twice daily in severe infections. CHILD: 36 mg/kg daily in 2 divided doses increased to 54 mg/kg/day in severe infections i) Severe or complicated ii) Treatment: ADULT & infections when oral therapy CHILD over 4 weeks: 1201498 Sulphamethoxazole 400 mg J01EE01961P3001X A is not feasible mg/kg/day PO/IV infusion in & Trimethoprim 80 mg X ii) Treatment and prophylaxis 2 - 4 divided doses for 14 Injection of pneumocystis carinii days. Prophylaxis: ADULT: pneumonia (PCP) in 960 mg once daily or 960 mg immunocompromised on alternate days (3 times a patients week) or 960 mg twice daily on alternate days (3 times a week). CHILD 6 weeks - 5 months: 120 mg twice daily on 3 consecutive days or 7 days per week; 6 months - 5 years: 240 mg; 6 - 12 years: 480 mg i) ADULT: 1 - 3 tablets twice daily ii) Treatment: ADULT & CHILD over 4 weeks: 1201499 Sulphamethoxazole 400 mg J01EE01961T1001X B i) Severe or complicated mg/kg/day in 2 - 4 divided & Trimethoprim 80 mg X infections due to susceptible doses for 14 days. Tablet infection Prophylaxis: ADULT: 960 mg ii) Treatment and prophylaxis once daily or 960 mg on of pneumocystis carinii alternate days (3 times a pneumonia (PCP) in week) or 960 mg twice daily immunocompromised on alternate days (3 times a patients week). CHILD; 6 weeks - 5 months: 120 mg twice daily on 3 consecutive days or 7 days per week; 6 months - 5 years: 240 mg; 6 - 12 years: 480 mg When used in scalp disorders, a small amount of cream should be rubbed gently into the roots of the1500 Sulphur 2% & Salicylic Acid D10AB02951G1001 C Acne vulgaris and hair. When used in skin 2% Cream XX seborrhoeic dermatitis disorders, the cream should be applied sparingly to the affected area. Apply once daily or until noticeable improvement, then once or twice a week 200-400 mg twice daily; 800 mg daily in predominantly Acute and chronic negative symptoms and 2.4 g1501 Sulpiride 200 mg Tablet N05AL01000T1001X B schizophrenia, chronic daily in mainly positive X delusional psychoses symptoms. Elderly, lower initial dose; increased gradually according toUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 276 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY response. Child under 14 years not recommended1502 Sumatriptan 100 mg Tablet N02CC01000T1002 A/KK Treatment of acute migraine 50 mg per attack and not XX attacks more than 300 mg daily1503 Sumatriptan 50 mg Fast N02CC01000T5001 A Treatment of acute migraine 50 mg per attack and not Disintegrating Tablet XX attacks more than 300 mg daily1504 Sumatriptan 50 mg Tablet N02CC01000T1001 A/KK Treatment of acute migraine 50 mg per attack and not XX attacks more than 300 mg daily 6 mg given by SC as soon as possible after onset. Dose may be repeated once after1505 Sumatriptan 6 mg/0.5 ml N02CC01000P5001 A Treament of acute migraine not less than 1 hour if Injection XX attacks and cluster headache needed. Max. 12 mg in 24 hours. Child not recommended Apply to exposed areas at least 30 minutes prior to solar1506 Sunscreen 5 - 20% w/w D02BA02000G1001 B Photodermatitis exposure; reapply after Cream XX swimming, prolonged perspiration and after 2 hours of continuos sun exposure Intravenous: Muscle relaxant in general anaesthesia Adult: As chloride: single dose of 0.3-1.1 mg/kg injected; supplementary doses of 50- 100% of the initial dose may be given at 5-10 min intervals. Max dose Suxamethonium Chloride M03AB01100P3001 Muscle relaxant as an (repeated IV injection or 50 mg/ml lnj XX adjunct to anaesthesia continuous infusion): 5001507 B mg/hr Child: As chloride: <1 yr: 2 mg/kg; 1-12 yr: 1 mg/kg. Intramuscular: Muscle relaxant in general anaesthesia Adult: As chloride: 3-4 mg/kg. Max total dose: 150 mg Child: As chloride: <1 yr: Up to 4-5 mg/kg; ≥1 yr: Up to 4 mg/kg. Max dose: 150 mg.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 277 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Diagnostic test for investigation of adrenocortical insufficiency Adult: As plain preparation: Measure plasma cortisol concentration immediately before and exactly 30 min after IM/IV inj of 250 mcg. Post-inj rise in plasma cortisol concentration ≥200 nmol/l (70 mcg/l) if normal adrenocortical function. As depot preparation (if Synthetic ACTH H01AA02000P3001X A Diagnostic test to inconclusive results with plain1508 (Tetracosactrin Acetate) X differentiate primary adrenal preparation): Measure from secondary (pituitary) plasma cortisol concentration 250 mcg/ml Injection adrenocortical insufficiency before and exactly 30 min, 1, 2, 3, 4 and 5 hr after an IM inj of 1 mg tetracosactide acetate depot. Adrenocortical function normal if the post-inj rise in plasma cortisol concentration increases 2- fold in 1st hr, and continues to rise steadily. Expected levels in 1st hr: 600-1,250 nmol/l, increasing slowly up to 1000-1800 nmol/l by 5th hr. Child: IV 250 mcg/1.73 m2 BSA. Intramuscular For short-term and intermittent long-term therapy Adult ≥16 years: Apply in the treatment of patients 0.03% or 0.1% to the with moderate to severe affected skin twice daily and atopic dermatitis in whom the rub in gently and completely. use of alternative, Children ≥ 2 years: Apply1509 Tacrolimus 0.03% Ointment D11AH01000G5002 A* conventional therapies are 0.03% ointment thinly to the XX deemed inadvisable because affected skin bd and rub in of potential risks, or in the gently and completely. treatment of patients who are Treatment should be not adequately responsive to continued for 1 week after or are intolerant of clearing of signs & symptoms alternative, conventional of atopic dermatitis. therapies For short-term and Adult ≥16 years: Apply intermittent long-term therapy 0.03% or 0.1% to the in the treatment of patients affected skin twice daily and with moderate to severe rub in gently and completely. atopic dermatitis in whom the Children ≥ 2 years: Apply D11AH01000G5001 use of alternative, 0.03% ointment thinly to the1510 Tacrolimus 0.1% Ointment XX A* conventional therapies are affected skin bd and rub in deemed inadvisable because gently and completely. of potential risks, or in the Treatment should be treatment of patients who are continued for 1 week after not adequately responsive to clearing of signs & symptoms or are intolerant of of atopic dermatitis.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 278 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY alternative, conventional therapies1511 Tacrolimus 0.5 mg Capsule L04AD02000C1003X A* i) Primary 0.1-0.2 mg/kg/day for liver X immunosuppression in liver transplantation and at 0.15- and kidney allograft 0.3 mg/kg/day for kidney Tacrolimus 0.5mg L04AD02000C2203X A* recipients. ii) Liver and transplantation administered1512 Prolonged-Release Hard X kidney allograft rejection as 2 divided doses. resistant to conventional Capsule immunosuppressive agents. i) Prophylaxis of kidney It is recommended to be transplant rejection: used concomitantly with Tacrolimus PR therapy adrenal corticosteroids. should commence at dose of Because of the risk of 0.20-0.30 mg/kg/day anaphylaxis. Injection should administered once daily in be reserved for patients the morning. Administration unable to take capsules only. should commence within 24 hours after completion of i) Prophylaxis of transplant surgery. rejection in adult kidney or ii) Prophylaxis of liver liver allograft recipients. transplant rejection: ii) Treatment of kidney or Tacrolimus PR therapy liver allograft rejection should commence at a dose resistant to treatment with of 0.10-0.20 mg/kg/day other immunosuppressive administered once daily in medicinal products in adult. the morning. Administration should commence within 12- 18 hours after completion of surgery. iii) Treatment of allograft rejection: Increased doses of tacrolimus, supplemental corticosteroid therapy, and introduction of short courses of mono- /polyclonal antibodies have all been used to manage rejection episodes. If signs of toxicity such as severe adverse reactions are noted, the dose of Tacrolimus PR might need to be reduced. iv) Treatment of allograft rejection after kidney or liver transplantation: For conversion from other immunosuppressants to onceUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 279 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY daily Tacrolimus PR, treatment should begin with the initial oral dose recommended in kidney and liver transplantation respectively for prophylaxis of transplant rejection. v) Conversion of Tacrolimus to Tacrolimus PR: Allograft transplant patients maintained on twice daily PR capsules dosing requiring conversion to once daily PR should be converted on a 1:1 (mg:mg) total daily dose basis. Tacrolimus PR should be administered in the morning. (Please refer to the product leaflet for further information on dosage) i) Primary immunosuppression in liver and kidney allograft recipients. ii) Liver and kidney allograft rejection resistant to 0.1-0.2 mg/kg/day for liver conventional transplantation and at 0.15-1513 Tacrolimus 1 mg Capsule L04AD02000C1001X A* immunosuppressive agents. 0.3 mg/kg/day for kidney X It is recommended to be transplantation administered used concomitantly with as 2 divided doses. adrenal corticosteroids. Because of the risk of anaphylaxis. Injection should be reserved for patients unable to take capsules only.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 280 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Prophylaxis of transplant i) Prophylaxis of kidney1514 Tacrolimus 1mg Prolonged- L04AD02000C2201X A* rejection in adult kidney or transplant rejection: Release Hard Capsule X liver allograft recipients. ii) Tacrolimus PR therapy Treatment of kidney or liver should commence at dose of allograft rejection resistant to 0.20-0.30 mg/kg/day treatment with other administered once daily in immunosuppressive the morning. Administration medicinal products in adult. should commence within 24 hours after completion ofUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) surgery. ii) Prophylaxis of liver transplant rejection: Tacrolimus PR therapy should commence at a dose of 0.10-0.20 mg/kg/day administered once daily in the morning. Administration should commence within 12- 18 hours after completion of surgery. iii) Treatment of allograft rejection: Increased doses of tacrolimus, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes. If signs of toxicity such as severe adverse reactions are noted, the dose of Tacrolimus PR might need to be reduced. iv) Treatment of allograft rejection after kidney or liver transplantation: For conversion from other immunosuppressants to once daily Tacrolimus PR, treatment should begin with the initial oral dose recommended in kidney and liver transplantation respectively for prophylaxis of transplant rejection. v) Conversion of Tacrolimus to Tacrolimus PR: Allograft transplant patients maintained on twice daily PR capsules dosing requiring conversion to once daily PR should be converted on a 1:1 (mg:mg) total daily dose basis. Tacrolimus PR should be administered in the morning. (Please refer to the product leaflet for further information on dosage) 281 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Primary immunosuppression in liver 0.1-0.2 mg/kg/day for liver1515 Tacrolimus 5 mg Capsule L04AD02000C1002X A* and kidney allograft transplantation and at 0.15- X recipients. 0.3 mg/kg/day for kidney ii) Liver and kidney allograft transplantation administered1516 Tacrolimus 5mg Prolonged- L04AD02000C2202X A* rejection resistant to as 2 divided doses. Release Hard Capsule X conventional immunosuppressive agents. i) Prophylaxis of kidney It is recommended to be transplant rejection: used concomitantly with Tacrolimus PR therapy adrenal corticosteroids. should commence at dose of Because of the risk of 0.20-0.30 mg/kg/day anaphylaxis. Injection should administered once daily in be reserved for patients the morning. Administration unable to take capsules only. should commence within 24 hours after completion of i) Prophylaxis of transplant surgery. rejection in adult kidney or ii) Prophylaxis of liver liver allograft recipients. transplant rejection: ii) Treatment of kidney or Tacrolimus PR therapy liver allograft rejection should commence at a dose resistant to treatment with of 0.10-0.20 mg/kg/day other immunosuppressive administered once daily in medicinal products in adult. the morning. Administration should commence within 12-Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 18 hours after completion of surgery. iii) Treatment of allograft rejection: Increased doses of tacrolimus, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes. If signs of toxicity such as severe adverse reactions are noted, the dose of Tacrolimus PR might need to be reduced. iv) Treatment of allograft rejection after kidney or liver transplantation: For conversion from other immunosuppressants to once daily Tacrolimus PR, treatment should begin with the initial oral dose recommended in kidney and liver transplantation 282 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY respectively for prophylaxis of transplant rejection. v) Conversion of Tacrolimus to Tacrolimus PR: Allograft transplant patients maintained on twice daily PR capsules dosing requiring conversion to once daily PR should be converted on a 1:1 (mg:mg) total daily dose basis. Tacrolimus PR should be administered in the morning. (Please refer to the product leaflet for further information on dosage)1517 Tacrolimus 5mg/ml Injection L04AD02000P3001X A* i) Primary 0.01-0.05 mg/kg for liver X immunosuppression in liver transplant and 0.05-0.1 and kidney allograft mg/kg for kidney transplant1518 Tamoxifen Citrate 20 mg L02BA01136T1001X A recipients. as 24-hours continuous Tablet X ii) Liver and kidney allograft infusion. rejection resistant to1519 Tamsulosin HCl 400 mcg G04CA02110T5001 A* conventional 20 mg in 1-2 divided doses. Extended Release Tablet XX immunosuppressive agents. Max: 40 mg/day It is recommended to be used concomitantly with 400 mcg once daily adrenal corticosteroids. Because of the risk of 283 / 314 anaphylaxis. Injection should be reserved for patients unable to take capsules only. Breast cancer Second line treatment of functional symptoms of benign prostatic hyperplasia (BPH) in patients who do not tolerate first line drugs or when first line drugs are inappropriate or contraindicatedUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1520 Tar, Coal Tar and Oleyl D05AA00952L5001X Dandruff, seborrhoeic Massage into wet hair, rinse Alcohol Liquid X A/KK dermatitis and atopic and repeat. Use once or dermatitis twice weekly Technetium-99m as Sodium pertechnetate is pertechnetate is obtained by elution with a sterile solution used for scintigraphy or of Sodium Chloride 0.9%. The dosage depend on type1521 Technetium-99m Sterile V09CA01000P3001X A* nuclear scan particularly of of scan Generator X the brain and thyroid to i) Thyroid scintigraphy: 18.5- prepare various technetium- 80 MBq (0.5-2.2 mCi) Scintigraphy performed 20 99m labelled injections for minutes after intravenous selective organ imaging injection ii) Salivary glandUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) scintigraphy: 40 MBq (1.1 mCi) Scintigraphy performed immediately after intravenous injection and at regular intervals up to 15 minutes iii) Meckel?s diverticulum scintigraphy: 400 MBq (10.8 mCi) Scintigraphy performed immediately after intravenous injection and at regular interval up to 30 minutes iv) Brain scintigraphy: 370- 800 MBq (10-22 mCi) Rapid sequential images are taken immediately within the first minute after intravenous administration, static images 1 to 4 hours later. Thyroid and coriod plexus should be blocked to avoid non-specific 99mTc uptake v) Cardiac and vascular scintigraphy: 740-925 MBq (20-25 mCi) Red cells are labeled in vivo or in vitro by pretreating with a reducing agent. Dynamic images are taken in the first minute after intravenous administration, followed by regular images over 30 minutes vi) Gastrointestinal bleeding: 740-925 MBq (20-25 mCi) Red cells are labeled in vivo or in vitro by pretreating with a reducing agent. Dynamic images are taken in the first minutes after intravenous administration, followed by regular images at appropriate intervals for up to 24 hours vii) Lacrimal duct scintigraphy: 2-4 MBq each 284 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY eye (50-100 mCi) Drops are instilled into eye and dynamic images are taken over 2 minutes, followed by static images at appropriate intervals over 20 minutes1522 Tegafur 100 mg & uracil L01BC53980C1001X A* Non small cell lung cancer 300-600 mg daily in 2-3 224 mg Capsule X divided doses ADULT and CHILD over 16 years: 600 mg once daily. Treatment of chronic Renal Dose Adjustment:1523 Telbivudine 600 mg Tablet J05AF11000T1001X A* hepatitis B in patients with 600mg every 48hours (30- X evidence of viral replication 49ml/min), 600 mg every and active liver inflammation 72hours. (<30ml/min; not requiring dialysis); 600mg every 96 days (ESRD)1524 Telmisartan 40 mg Tablet C09CA07000T1001X A/KK Hypertension in patients who 40mg - 80mg once daily X cannot tolerate ACE inhibitors because of cough Telmisartan 80 mg & C09DA07000T1001X A/KK Hypertension in patients who 1 tablet daily1525 Hydrochlorothiazide 12.5 X cannot tolerate ACE inhibitors because of cough mg Tablet Treatment of essential hypertension in adults: i) Replacement therapy:Patients receiving telmisartan and amlodipine from separate tablets may instead receive one tablet Single-pill combination containing the same should be taken once daily. component doses Initiate with telmisartan1526 Telmisartan 80 mg and C09DB04935T1002X A/KK ii) Add on therapy: Patients 80mg/amlodipine 5mg one Amlodipine 10 mg Tablet X who blood pressure is not tablet per day. The maximum adequately controlled on recommendation dose is telmisartan or amlodipine telmisartan 80mg/amlodipine monotherapy 10mg one tablet per day. iii) Initial therapy: May also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goalsUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 285 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1527 Telmisartan 80 mg and C10BX03935T1008X Treatment of essential Single-pill combination Amlodipine 5 mg Tablet X A/KK hypertension in adults: i) should be taken once daily. Replacement Initiate with telmisartan1528 Telmisartan 80 mg Tablet C09CA07000T1002X A/KK therapy:Patients receiving 80mg/amlodipine 5mg one X telmisartan and amlodipine tablet per day. The maximum from separate tablets may recommendation dose is instead receive one tablet telmisartan 80mg/amlodipine containing the same 10mg one tablet per day. component doses ii) Add on therapy: Patients who blood i) 40mg - 80mg once daily pressure is not adequately ii) 80mg once daily controlled on telmisartan or amlodipine monotherapy iii) Concomitant phase: Initial therapy: May also be 75mg/m2 daily with used as initial therapy in radiotherapy for 42 days, patients who are likely to followed by 6 cycle of need multiple drugs to adjuvant treatment. Adjuvant achieve their blood pressure phase: Additional 6 cycles of goals adjuvant phase. Cycle 1- i) Hypertension in patients 150mg/m2 once daily for 5 who cannot tolerate ACE days followed by 23 days inhibitors because of cough without treatment. Cycle 2-6 : ii) Reduction of the risk of 200mg/m2 once daily for 5 myocardial infarction, stroke, days per 28-day cycle or death from cardiovascular Concomitant phase: causes in patients 55 years 75mg/m2 daily with or older at high risk of radiotherapy for 42 days, developing major followed by 6 cycle of cardiovascular events who adjuvant treatment. Adjuvant are unable to take ACE phase: Additional 6 cycles of inhibitors adjuvant phase. Cycle 1- 150mg/m2 once daily for 5 In patients with glioblastoma days followed by 23 days without treatment. Cycle 2-6 : multiforme who fulfill all the 200mg/m2 once daily for 5 following criteria: days per 28-day cycle1529 Temozolomide 100 mg L01AX03000C1003X A* i. Total /near total resection Capsule X ii. ECOG/WHO performance status 0-2 iii. Age less than 60 years In patients with glioblastoma multiforme who fulfill all the1530 Temozolomide 20 mg L01AX03000C1001X A* following criteria: Capsule X i. total /near total resection ii. ECOG/WHO performance status 0-2 iii. Age less than 60 yearsUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 286 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Acute myocardial reinfarction where streptokinase is Less than 60 kg: 30 mg, 60 - Tenecteplase 10,000 unit contraindicated due to 69 kg: 35 mg, 70 - 79 kg: 40 (50 mg) Injection B01AD11000P4001X previous streptokinase mg; 80 -90 kg: 45 mg, 90 kg1531 X A* induced antibodies. or above: 50 mg. Administer [Indicated when antibodies single IV bolus over 5-10 was given more than 5 days seconds and less than 12 months] Treatment of HIV-1 infection in adults in combination with1532 Tenofovir Disoproxil J05AR03964T1001X A/KK other antiretroviral agents 1 tablet once daily. Fumarate 300 mg & X (such as non-nucleoside Emtricitabine 200 mg Tablet reverse transcriptase inhibitors or protease inhibitors). i) Treatment of HIV-1 infected1533 Tenofovir Disoproxil J05AF07138T1001X A* adults in combination with 300mg once daily. Renal Fumarate 300 mg Tablet X other antiretroviral agents. Dose Adjustment: 300mg ii) Use as first line every 48hours (30-49ml/min); monotherapy for chronic 300mg every 72hours (10- hepatitis B or as a rescue 29ml/min); 300mg every 7 therapy for patients with drug days after dialysis resistance hepatitis B virus (Hemodialysis) (according to resistant profile or treatment guidelines). G04CA03110T1001 Only for treatment of Benign Initially 1 mg at night, XX Prostatic Hyperplasia. Not to increased in a stepwise1534 Terazosin HCl 1 mg Tablet A/KK be used for treatment of fashion to 2 mg, 5 mg or 10 hypertension mg once daily i) Initially 1 mg at night, increased in a stepwise fashion to 2 mg, 5 mg or 101535 Terazosin HCl 2 mg Tablet G04CA03110T1002 i) Treatment of Benign mg once daily. XX A/KK Prostatic Hyperplasia. ii) Initial: 1mg once daily at bedtime, Maintenance: 1- ii) Hypertension 5mg once (morning or evening) or twice daily. Max: 20-40mg/day i) Initially 1 mg at night, increased in a stepwise fashion to 2 mg, 5 mg or 101536 Terazosin HCl 5 mg Tablet G04CA03110T1003 i) Treatment of Benign mg once daily. XX A/KK Prostatic Hyperplasia. ii) Initial: 1mg once daily at bedtime, Maintenance: 1- ii) Hypertension 5mg once (morning or evening) or twice daily. Max: 20-40mg/day1537 Terbinafine HCl 250 mg D01BA02110T1001X A/KK Fungal infections especially 250 mg once daily for 6 Tablet X onchomycosis caused by weeks for fingernails: 12 dermatophytes weeks for toenails ADULT and CHILD more Bronchial asthma, chronic than 12 years: 1 inhalation 61538 Terbutaline 0.5mg/dose R03AC03183A2001 B bronchitis, emphysema and hourly. Severe cases: Single Inhaler XX other lung diseases where dose may be increased to 3 bronchospasm is a inhalation. Maximum 12 complicating factor inhalation/24 hour. CHILD 3- 12 year: 1 inhalation 6 hourly.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 287 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Severe cases: Single dose may be increased to 2 inhalation. Maximum 8 inhalation/24 hour SC, IM or slow IV: 250-500 mcg up to 4 times daily. CHILD 2 - 15 years1539 Terbutaline Sulphate 0.5 R03CC03183P3001 B Bronchial asthma, chronic mg/ml Injection XX 10mcg/kg to a maximum of bronchitis, emphysema and 300 mcg. Continuous IV other lung diseases where infusion, as a solution broncoconstriction is a complicating factor containing 3 - 5 mcg/ml, 1.5 - 5 mcg/minute for 8 - 10 hours; reduce dose for children ADULT: 5 - 10 mg 2 -4 times daily, additional doses may1540 Terbutaline Sulphate 10 R03AC03183A3001 B Asthma and other conditions be necessary in severe acute mg/ml Nebulizer Solution XX associated with reversible asthma. CHILD up to 3 years airways obstruction : 2 mg, 3 - 6 years : 3 mg, 6 - 8 years : 4 mg, over 8 years : 5 mg 2 - 4 times daily 2 mg IV bolus over 1 minute. Maintenance: 1 - 2 mg IV1541 Terlipressin 1mg/5mg H01BA04000P4001X A* Acute oesophageal variceal bolus 4 - 6 hourly until Injection X bleeding bleeding is controlled, up to 24 - 36 hours. The maximum daily dosage is 120-150 mcg/kg body weight. By IM only. Hypogonadism 250 mg every 2-3 weeks. To Only for treatment of male maintain an adequate infertility, protein deficiency androgenic effect 250 mg1542 Testosterone 250 mg/ml G03BA03000P3001 during convalescence after every 3-6 weeks. Potency Injection XX A* surgery and wasting disorder. disorders 250 mg every 4 In women, supplementary weeks. Male climateric therapy of progressive disorders: 250 mg every 3-4 mammary carcinoma weeks. Repeated 6-8 weeks courses at 2-3 months interval 2 doses of 0.5 mL IM at an1543 Tetanus Toxoid Injection J07AM01000P3001X C+ Immunization against tetanus interval of 4-8 wk, followed by X infection the 3rd dose 6-12 mth later. Booster: 0.5 mL IM every 10 yr.1544 Tetracycline HCl 250 mg J01AA07110C1001X B Infections caused by Adult: 250-500 mg 6 hrly. Capsule X susceptible pathogens Max: 4 g/day. Child: ≥12 yr Max: 2 g daily1545 Tetracycline HCl 250 mg J01AA07110T1001X B Infections caused by Adult: 250-500 mg 6 hrly. Tablet X susceptible pathogens Max: 4 g/day. Child: ≥12 yr Max: 2 g dailyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 288 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY First line induction therapy in newly diagnosed multiple myeloma, salvage therapy in relapsed multiple myeloma1546 Thalidomide 50 mg Capsule L04AX02000C1001X A* and maintenance therapy in 50 mg to 200 mg daily X multiple myeloma (contraindicated for pregnant women; pregnancy test for females in reproductive age group before starting treatment should be done). Used in myocardial perfusion scintigraphy, acute myocardial infarction and post-surgical assessment of1547 Thallous Chloride (Thallium- V09GX01100P3001 A* coronary artery bypass graft As IV infusion 201) Injection XX patency, muscle perfusion scintigraphy, visualisation of brain and thyroid tumours and metastases ADULT: 125 mg 3 - 4 times1548 Theophylline 125 mg Tablet R03DA04000T1001X B Reversible airways daily after food, increased to X obstruction, acute severe 250 mg if required. CHILD: 1 asthma - 15 years : 5 mg/kg/dose (up to 600 mg/ day) every 3 - 4 times daily1549 Theophylline 250 mg Long R03DA04000T5001X B Reversible airways ADULT: 250 mg 2 times Acting Tablet X obstruction and acute severe asthma daily. CHILD under 12 years : Up to 10 mg/kg body weight 2 times daily ADULT: 125 mg 3 - 4 times daily after food, increased to1550 Theophylline 80 mg/15 ml R03DA04000L9001X B Reversible airways 250 mg if required. CHILD 1 - Syrup X obstruction and acute severe 15 years : 5 mg/kg/dose (up asthma to 600 mg/day) every 3 - 4 times per day1551 Thiamine HCl 100 mg/ml A11DA01110P3001X B i) For the prevention or i) Mild to chronic deficiency: Injection X treatment of Vitamin B1 10-25 mg daily. Severe deficiency syndromes including beri-beri and deficiency: 200- 300 mg daily peripheral neuritis associated ii) 500 mg every 8 hours for 2 with pellagra ii) Wernicke-Korsakoff days, followed by 100 mg 2 Syndrome times daily until patient can take oral dose1552 Thiamine Mononitrate 10 A11DA01221T1002X C i) For the prevention or i) Mild to chronic deficiency: mg Tablet X treatment of Vitamin B1 10-25 mg daily. Severe deficiency syndromes deficiency: 200- 300 mg daily including beri-beri and ii) 500 mg every 8 hours for 2 peripheral neuritis associated days, followed by 100 mg 2 with pellagra times daily until patient can ii) Wernicke-Korsakoff take oral dose Syndrome i) For the prevention or i) Mild to chronic deficiency:1553 Thiamine Mononitrate 3 mg A11DA01221T1001X C treatment of Vitamin B1 10-25 mg daily. Severe Tablet X deficiency syndromes deficiency: 200 - 300 mg including beri-beri and daily peripheral neuritis associated ii) 500 mg every 8 hours for 2Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 289 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY with pellagra days, followed by 100 mg 2 ii) Wernicke-Korsakoff times daily until patient can Syndrome take oral dose Refer to specific protocols. Usually 100 mg/m2 for 5 - 7 days (acute myeloid1554 Thioguanine 40 mg Tablet L01BB03000T1001X A For acute leukaemia and leukaemia) or up to 2 weeks X chronic granulocytic (chronic myeloid leukaemia leukaemia for accelerated/ advanced disease). CHILD: 40 - 60 g/m2 daily according to protocol i) ADULT: For induction 200 - 400 mg. For repeat injection 3 - 5 mg/kg over 10 - 15 i) General anaesthesia, seconds until desired depth1555 Thiopental Sodium 500 mg N05CA19520P3001 B induction of anaesthesia is obtained. Injection XX ii) Anticonvulsant for cases Not FDA approved for use in resistant to conventional pediatric patients anticonvulsants in the ICU ii) 75 - 125 mg IV single dose; for local-anaesthetic induced convulsion: 125 - 250 mg IV over 10 minutes1556 Thymol Compound Gargle A01AD11985M2001 C For sore throat and minor To be gargled 3-4 times daily XX mouth inflammation A two-injection regimen is recommended for thyrotropin administration.The two- injection regimen is thyrotropin 0.9 mg intramuscularly (IM), followed by a second 0.9 mg IM injection 24 hours later. After1557 Thyrotropin alfa 0.9mg/ml H01AB01000P3002X A* Thyrogen (thyrotropin alfa) is reconstitution with 1.2 mL Injection X indicated for use as an Sterile Water for Injection, adjunctive treatment for 1.0 mL solution (0.9 mg radioiodine ablation of thyroid thyrotropin alfa) is tissue remnants in patients administered by who have undergone a near- intramuscular injection to the total or total thyroidectomy buttock. For radioiodine imaging or treatment, for well-differentiated thyroid radioiodine administration cancer and who do not have should be given 24 hours evidence of distant following the final Thyrogen metastatic thyroid cancer. injection. Diagnostic scanning should be performed 48 hours after radioiodine administration, whereas post-therapy scanning may be delayed additional days to allow background activity to decline.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 290 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE1558 Tibolone 2.5 mg Tablet G03CX01000T1001 CATEGORY Treatment of complaints 2.5mg daily1559 Ticagrelor 90 mg Tablet XX A* resulting from the natural or surgical menopause & in Initially, 180mg as single1560 Ticlopidine HCl 250 mg B01AC24000T1001X A* cases at high risk for breast dose followed by 90mg bd Tablet X carcinomas where general with maintenance dose of A/KK hormone replacement ASA 75-150 mg daily.1561 Timolol Maleate 0.5% Eye B01AC05110T1001X A therapy is contraindicated Drops X B a) Patient who failed 250 mg twice daily taken with clopidogrel readmitted to food1562 Tinidazole 500 mg Tablet S01ED01253D2002 hospital with recurrent XX atherothrombotic event while Initially, 1 drop of 0.25% 2 patients are on clopidogrel. times daily, if clinical P01AB02000T1001X b) ACS patients with: response is not adequate, 1 X i) STEMI - going for invasive drop of 0.5% 2 times daily (PCI), i) ADULT: 2 g as a single ii) NSTEMI/UA - intermediate dose for 2 - 3 days. CHILD 3 to high risk (based on TIMI years and older: 50 mg/kg score). daily for 3 days iii) Other complicated ACS ii) ADULT: 2 g as a single cases treated either dose (repeated once if medically or invasively via necessary). Sexual partners PCI or CABG (risk of Stent should be treated thrombosis, 3VD etc.) concomitantly with the same i) Prevention of thrombotic dose. CHILD 6 years and stroke for patients who are older : single dose of 1 gram sensitive /intolerant to Acetysalicylic Acid ii) Maintenance of coronary bypass surgery or angioplasty iii) Maintenance of patency of access in patients on chronic haemodialysis Elevated intraocular pressure, chronic open angle glaucoma i) Amoebiasis ii) Urogenital trichomoniasis and giardiasisUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 291 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Treatment of DVT and PE, i) Treatment of deep vein in conjunction with warfarin: thrombosis (DVT) and 175 anti-Factor Xa IU/kg SC once daily for at least 6 days. Tinzaparin sodium 10,000 B01AB10520P5001X pulmonary embolism (PE), ii) Thromboprophylaxis in anti-Factor Xa IU/ml X not amounting to patients with: Moderate risk1563 Injection in Prefilled A* hemodynamic instability. of thrombosis (general ii) Prevention of post- surgery):3,500 anti-Factor Xa syringe/cartridge operative DVT in patients IU SC 2 hrs before surgery and postoperatively, 3,500 undergoing general and anti-Factor Xa IU once daily for 7-10 days. High risk of orthopaedic surgery. thrombosis (eg. total hip replacement):4,500 anti- i) Treatment of deep vein Factor Xa IU SC or 50 anti- thrombosis (DVT) and Factor Xa IU/kg body weight SC 2 hrs before surgery and Tinzaparin sodium 20,000 B01AB10520P5002X pulmonary embolism (PE), then once daily until the anti-Factor Xa IU/ml X not amounting to patients has been mobilized.1564 Injection in Prefilled A* hemodynamic instability. i) Treatment of DVT and PE, ii) Prevention of post- in conjunction with warfarin: syringe/cartridge operative DVT in patients 175 anti-Factor Xa IU/kg SC once daily for at least 6 days. undergoing general and ii) Thromboprophylaxis in patients with: Moderate risk orthopaedic surgery. of thrombosis (general surgery):3,500 anti-Factor Xa Skin fungal infections IU SC 2 hrs before surgery and postoperatively, 3,5001565 Tioconazole 1% Cream D01AC07000G1001 A resistant to antifungal drugs anti-Factor Xa IU once daily XX such as miconazole and for 7-10 days. High risk of clotrimazole thrombosis (eg. total hip replacement):4,500 anti-1566 Tioconazole 100 mg G01AF08000S1001X A Vulvovaginal candidiasis Factor Xa IU SC or 50 anti- Vaginal Tablet X Factor Xa IU/kg body weight SC 2 hrs before surgery and1567 Tioconazole 6.5% Vaginal G01AF08000G5001 A Vulvaginal candidiasis then once daily until the Ointment XX patients has been mobilized. Gently massage into the affected and surrounding area 1-2 times daily Adult & Child > 12yr: Insert nightly on retiring for 3-6 or 14 days Apply 4.6 g intravaginally prior to bedtime as a single dose therapy, therapy may extend to 7 daysUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 292 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD) in which the diagnosis of COPD is confirmed by spirometry. ii) As add-on maintenance1568 Tiotropium 2.5mcg/puff R03BB04320A3001X A/KK bronchodilator treatment in 5 mcg (2 puff) once daily, at solution for inhalation X adult patients with asthma the same time of the day who are currently treated with the maintenance combination of inhaled corticosteroids (≥800µg budesonide/day or equivalent) and long-acting β2-agonist and who experienced one or more severe exacerbations in the previous year. Long term maintenance treatment of bronchospasm and dypsnoea associated1569 Tiotropium Bromide 18 mcg R03BB04320C9901 A/KK with COPD. Tiotropium has Contents of one capsule is Inhalation Capsules XX usually been added to inhaled once daily with the standard therapy (e.g. Handihaler inhalation device inhaled steroids, at the same time of the day. theophylline, albuterol rescue) Unstable angina or non-ST segment elevation myocardial infarction with the By IV infusion, 0.41570 Tirofiban HCl 0.25 mg/ml B01AC17110P9901X A* following: elevated cardiac mcg/kg/min for 30 minutes, Injection X markers, refractory chest then 0.1 mcg/kg/min for at pain, ST-segment changes least 48 hours, maximum 108 and thrombolysis in hours myocardial infarction (TIMI) risk score 4 Indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in Recommended dose for adult patients: rheumatoid arthritis of i) with inadequate respond or tocilizumab for adult patients intolerance to conventional is 8mg/kg given once every 4 disease- modifying weeks as a single-drip IV antirheumatic drugs infusion over 1 hour. It should1571 Tocilizumab 20 mg/ml L04AC07000P3001X A* (DMARDS) be diluted to 100 ml by a Injection X ii) who has failed antitumour healthcare professional with necrosis factors (antiTNFs) sterile 0.9% w/v sodium iii) where TNF is chloride solution over 1 hour. contraindicated (patients with For patients whose body history of pulmonary weight is more than 100kg, tuberculosis [PTB]) It also doses exceeding 800mg per can be used as monotherapy infusion are not or with combination with recommended methotrexate (MTX) and/ or other DMARDS.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 293 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1572 Tolterodine Tartrate ER 4 G04BD07123C2002 Treatment of overactive 4 mg once daily. May mg Capsule XX A* bladder with symptoms of decrease to 2 mg once daily urinary, frequency or urge depending on response and incontinence tolerability1573 Topiramate 100 mg Tablet N03AX11000T1003X A* Add-on therapy for ADULT: Initially 25-50mg X intractable partial epilepsy nightly for 1 week. Subsequently at wkly or bi-1574 Topiramate 15 mg Capsule N03AX11000C1001 A* Add-on therapy for wkly intervals, increase dose Sprinkle XX intractable partial epilepsy by 25-50 to 100mg/day in 2 divided doses. CHILD aged 21575 Topiramate 25 mg Capsule N03AX11000C1002 A* Add-on therapy for and above: Approx 5-9 Sprinkle XX intractable partial epilepsy mg/kg/day in 2 divided doses. Titrate at 25mg (or less, based on a range of 1- 3mg/kg/day) nightly for the 1st week. Subsequently at 1 or 2 wkly intervals, with increments of 1-3 mg/kg/day in 2 divided dose. ADULT: Initially 25-50mg nightly for 1 week. Subsequently at wkly or bi- wkly intervals, increase dose by 25-50 to 100mg/day in 2 divided doses. CHILD aged 2 and above: Approx 5-9 mg/kg/day in 2 divided doses. Titrate at 25mg (or less, based on a range of 1- 3mg/kg/day) nightly for the 1st week. Subsequently at 1 or 2 wkly intervals, with increments of 1-3 mg/kg/day in 2 divided dose. ADULT: Initially 25-50mg nightly for 1 week. Subsequently at wkly or bi- wkly intervals, increase dose by 25-50 to 100mg/day in 2 divided doses. CHILD aged 2 and above: Approx 5-9 mg/kg/day in 2 divided doses. Titrate at 25mg (or less, based on a range of 1- 3mg/kg/day) nightly for the 1st week. Subsequently at 1 or 2 wkly intervals, with increments of 1-3 mg/kg/day in 2 divided dose.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 294 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULT: Initially 25-50mg1576 Topiramate 25 mg Tablet N03AX11000T1001X A* Add-on therapy for nightly for 1 week. X intractable partial epilepsy Subsequently at wkly or bi- wkly intervals, increase dose1577 Topiramate 50 mg Tablet N03AX11000T1002X A* Add-on therapy for by 25-50 to 100mg/day in 2 X intractable partial epilepsy divided doses. CHILD aged 2 and above: Approx 5-9 Only to be used to cover mg/kg/day in 2 divided doses. Titrate at 25mg (or1578 Trace Elements and B05XA30905P3001X A* daily loss of electrolyte and less, based on a range of 1- Electrolytes (Adult) Solution X trace elements for patient on 3mg/kg/day) nightly for the parenteral nutrition 1st week. Subsequently at 1 or 2 wkly intervals, with Trace Elements and B05XA30905P3002X A* Only to be used to cover increments of 1-3 mg/kg/day1579 Electrolytes (Paediatric) X daily loss of electrolyte and in 2 divided dose. trace elements for patient on ADULT: Initially 25-50mg Solution parenteral nutrition nightly for 1 week. Subsequently at wkly or bi- Post-operative pain, chronic wkly intervals, increase dose by 25-50 to 100mg/day in 21580 Tramadol HCl 100 mg N02AX02110S2001X A cancer pain, analgesia/pain divided doses. CHILD aged 2 Suppository X relief for patients with and above: Approx 5-9 mg/kg/day in 2 divided impaired renal function doses. Titrate at 25mg (or less, based on a range of 1- Post-operative pain, chronic 3mg/kg/day) nightly for the Tramadol HCl 100 mg/ml N02AX02110D5001 cancer pain, analgesia/pain 1st week. Subsequently at 11581 Drops XX A relief for patients with or 2 wkly intervals, with increments of 1-3 mg/kg/day impaired renal function. in 2 divided dose. 10 ml added to 500-1000 ml solution, given by IV infusion According to the needs of the patient. INFANT and CHILD weighing 15 kg or less: Basal requirements of the included trace elements are covered by 1 ml/kg/day to a maximum dose of 15 ml. CHILD weighing 15 kg or more, a daily dose of 15 ml, should meet basic trace element requirements. However, for patients weighing more than 40 kg the adult preparation trace element should be used 100mg rectally up to qds 50 - 100 mg every 4 hours. Max: 400 mg daily. Not recommended in childrenUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 295 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Moderate to severe acute or ADULT: 50mg initially, can chronic pain (eg. Post- take another 50mg after 30 -1582 Tramadol HCl 50 mg N02AX02110C1001 operative pain, chronic 60 min if pain not relieved. Capsule XX A/KK cancer pain and Max 400 mg daily. CHILD: 1mg/kg/dose repeated every analgesia/pain relief for patients with impaired renal 6 hours (Max: 2mg/kg/dose function) and 100mg/dose) Moderate to severe acute or ADULT: IV/IM/SC 50 - chronic pain (eg. Post- 100mg. (IV inj over 2-3 min operative pain, chronic or IV infusion). Initially 1001583 Tramadol HCl 50 mg/ml N02AX02110P3001X A cancer pain and mg then 50 - 100 mg every 4 Injection X analgesia/pain relief for - 6 hours. . Max: 400 mg patients with impaired renal daily. CHILD (1 year and function) above): 1 - 2mg/kg/dose ADULT: Slow IV 0.5-1 g (10 - 15 mg/kg) 3 times daily.1584 Tranexamic Acid 100 mg/ml B02AA02000P3001X B Haemorrhage associated Continuous infusion at a rate Injection X with excessive fibrinolysis of 25 - 50 mg/kg daily. CHILD: slow IV 10 mg/kg/day 2-3 times daily ADULT: 1-1.5 g (15-25 mg/kg) 2-4 times daily. Tranexamic Acid 250 mg B02AA02000C1001X CHILD: 25 mg/kg/day 2-3 Capsule X Haemorrhage associated times daily. Menorrhagia1585 B with excessive fibrinolysis (initiated when menstruation has started), 1 g 3 times daily for up to 4 days; maximum 4 g daily Used only in adjuvant setting for patients with HER2 over- Initial loading dose is 4 mg/kg expressed breast cancer, administered as a 90 minutes that is HER2 3+ by IV infusion. Subsequent1586 Trastuzumab 440 mg L01XC03000P4001X A* immunohistochemistry and doses is 2 mg/kg Injection X over-expressed by FISH administered as 30 minutes (Fluorescence in situ IV infusion weekly for 51 hybridization) and high risk weeks group To decrease intraocular pressure (IOP) in patients1587 Travoprost 0.004% & S01ED51990D2003 A* with open-angle glaucoma or 1 drop in the affected eye(s) Timolol 0.5% Eye Drops XX ocular hypertension who are once daily insufficiently responsive to other topical anti glaucomas Apply thinly to the affected1588 Tretinoin 0.01% Gel D10AD01000G3001 A/KK Acne vulgaris, recalcitrant area once daily or twice daily. XX cases of acne (comedonal Avoid exposure to sunlight. type) Duration of treatment: 8-12 weeks is required before any noticeable response Apply thinly to the affected1589 Tretinoin 0.05% Cream D10AD01000G1001 A/KK Acne vulgaris and recalcitrant area once daily or twice daily. XX cases of acne (comedonal Avoid exposure to sunlight. type) Duration of treatment: 8 - 12 weeks is required before any noticeable responseUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 296 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Apply thinly to the affected area once daily or twice daily.1590 Tretinoin 0.1% Cream D10AD01000G1002 A Acne vulgaris and recalcitrant Avoid exposure to sunlight. XX cases of acne (comedonal Duration of treatment: 8 - 12 type) weeks is required before any noticeable response1591 Triamcinolone Acetonide A01AC01351G3101 B Oral and perioral lesions Apply a thin layer to affected 0.1% Oral Paste XX area 2-4 times daily Smaller joints: 2.5 - 5 mg and1592 Triamcinolone Acetonide 10 H02AB08351P3001X A Inflammation of joints, bursae larger joints: 5 - 15 mg. mg/ml Injection X and tendon sheaths Treatment should be limited to 1 mg/injection site to prevent cutaneous atrophy Allergies, dermatoses,1593 Triamcinolone Acetonide 40 H02AB08351P3002X A/KK rheumatoid arthritis and 40-80 mg deep into the mg/ml Injection X inflammatory opthalmic gluteal muscle diseases ADULT: Initially 5 mg twice daily, increase by 5 mg after 1 week, then at 3-day1594 Trifluoperazine HCI 5 mg N05AB06110T1001X B Psychotic disorder intervals. Maximum 40 Tablet X mg/day. CHILD up to 12 years: Initially up to 5 mg daily in divided doses adjusted to response, age and body weight1595 Trimetazidine 20 mg Tablet C01EB15110T1001X B Prophylactic treatment of 20 mg 3 times daily X episodes of angina pectoris1596 Trimetazidine 35 mg MR C01EB15110T5001X B Prophylactic treatment of 35 mg twice daily in the Tablet X episodes of angina pectoris morning and evening with meals ADULT: 200 mg daily in 1 or 2 divided doses or 300 mg daily as a single dose. Acute1597 Trimethoprim 100 mg J01EA01000T1001X B Treatment of urinary tract infection: 200 mg twice daily. Tablet X infections due to susceptible CHILD: 6-8 mg/kg/day in 2 pathogens divided doses. 6 - 12 years: 100 mg twice daily; 6 months - 5 years: 50 mg twice daily. 6 weeks - 5 months: 25mg twice daily ADULT: 200 mg daily in 1 or 2 divided doses or 300 mg daily as a single dose. Acute Treatment of urinary tract infection: 200 mg twice daily.1598 Trimethoprim 300 mg J01EA01000T1002X B infections due to susceptible CHILD: 6 - 12 years: 100 mg Tablet X pathogens twice daily; 6 months - 5 years: 50 mg twice daily. 6 weeks - 5 months: 25mg twice daily 5 - 10 mg daily, 2 - 4 hours1599 Trioxsalen 5 mg Tablet D05BA01000T1001X A Vitiligo before exposure to sunlight. X To increase pigmentation: 10 mg daily, 2 hours prior to UV irradiationUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 297 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Decongestion of the upper respiratory tract in common Triprolidine HCl 1.25 mg R01BA52110L9001X B cold, hay fever, allergic and ADULT and CHILD more1600 and Pseudoephedrine HCl X vasomotor rhinitis and than 12 year : 10 ml. CHILD sinusitis. Doses to be taken 6 - 12 years : 5 ml 2 - 5 years 30 mg per 5 ml Syrup twice daily or three times : 2.5 ml daily ADULT 2.5 mg every 4 - 6 hours; maximum dose 10 mg/day. CHILD (syrup) 6 - 12 Decongestion of the upper years : 1.25 mg every 4 - 61601 Triprolidine HCl 2.5 mg and R01BA52988T1002X B respiratory tract in common hours; maximum dose 5 Pseudoephedrine HCl 60 X cold, hay fever, allergic and mg/day 4 - 6 years : 0.938 mg Tablet vasomotor rhinitis and mg every 4 - 6 hours; aerotitis maximum dose 3.744 mg/day 2 - 4 years : 0.625 mg every 4 - 6 hours; maximum dose 2.5 mg/day 1 intramuscular injection1602 Triptorelin 3.75 mg Injection L02AE04000P2001X A i) Treatment of confirmed every 4 weeks. The X central precocious puberty treatment must be started in (preterm sexual the first 5 days of the development) in girls under 9 menstrual cycle. The duration years, boys under 10 years of treatment depends on the of age initial severity of the ii) Genital and extragenital endometriosis and the endometriosis (stage I to changes observed in the stage IV). Treatment should clinical features. In principle, not be administered for more the treatment should be than 6 months. It is not administered for at least 4 recommended to start a months and for at most 6 second treatment course with months. It is not triptorelin or another GnRH recommended to start a analogue. second treatment course with triptorelin or another GnRH analogue.1603 Tropicamide 1% Eye Drops S01FA06000D2002X A/KK Topical use to produce 1 - 2 drops several times a X cycloplegic refraction for day diagnostic purposes Symptomatic treatment for urge incontinence and/or1604 Trospium Chloride 20mg G04BD09100C1001 A* increased urinary frequency 1 tablet twice daily. Tablet coated tablet XX and urgency as may occur in should be swallowed whole patients with overactive with a glass of water before bladder (eg. Idiopathic or meals on empty stomach. neurologic detrusor Severe renal impairment overactivity) Place in therapy: (CrCl between 10 & 30 As first line treatment for mL/min/1.73 m2): 1 tab daily overactive bladder in patients or every 2nd day with Parkinsonism, Alzheimer's or other cognitive disease1605 Tuberculine PPD Injection V04CF01000P3001X B For routine Mantoux 10 units is injected X (tuberculin sensitivity) test intradermally1606 Typhoid Vaccine Capsule J07AP01000C1001X B Active immunization against ADULT and CHILD 6 years X typhoid fever in adult and of age or older, 1 capsule on child 6 years of age or older days 1, 3 and 5Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 298 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1607 Typhoid Vaccine Injection J07AP02000P3001X B Active immunization against 0.5 ml single IM injection into (20 doses) X typhoid fever in adult and the deltoid or vastus lateralis, child more than 2 years may reimmunize with 0.5 ml IM every 3 years if needed. Dosage is one tablet to be Emergency contraception taken orally as soon as within 4-5 days of possible, but no later than Ulipristal Acetate 30mg G03AD02122T10011608 Tablet XX A unprotected sexual 120 hours (5 days) after intercourse for sexual assault unprotected sexual victim. intercourse or contraceptive failure. To be individualized. 75 IU- 150 IU daily and maybe1609 Urofollitropin (FSH) 150 IU G03GA04000P3002 A* Stimulation of follicular increased or decreased by Injection XX growth in infertile women up to 75 IU/day at 7 or 14 day intervals if necessary To be individualized. 75 IU-1610 Urofollitropin (FSH) 75 IU G03GA04000P3001 A* Stimulation of follicular 150 IU daily and maybe Injection XX growth in infertile women increased or decreased by up to 75 IU/day at 7 or 14 day intervals if necessary ADULT: Acute pulmonary embolism: IV loading dose 4400 iu/kg over 10 mins, maintenance 4400 iu/kg/hour for 12 hours. Peripheral Treatment of thromboembolic vascular occlusion: infuse disease such as mycocardial 2500 iu/ml into clot at a rate1611 Urokinase 6000 IU Injection B01AD04000P4001X A infarction, peripheral artery of 4000 iu/min for 2 hours. X occlusion, pulmonary This may be repeated up to 4 embolism, retinal artery times. Hyphaema: 5000 IU in thrombosis and other 2 ml saline solution is ophthalmologic use injected and withdrawn repeatedly over the iris. If residual clot remains, leave 0.3ml in the anterior chambers for 24-48 hours to facilitate futher dissolution 10-15 mg/kg daily in 2 to 4 divided doses usually for 3 Cholestatic liver diseases months to 2 years. If there is1612 Ursodeoxycholic Acid 250 A05AA02000C1001X A (eg. primary biliary cirrhosis, no decrease in stone size mg Capsule X primary cholangitis etc) after 18 months, further treatment seems not to be useful1613 Ustekinumab 90 mg/ml L04AC05000P3002X A* Treatment of moderate to Body weight less than 100kg: Injection X severe plaque psoriasis in Initial dose of 45 mg SC, adults who failed to, or who followed by 45 mg 4 weeks have contraindication to, or later, then every 12 weeks are intolerant to conventional thereafter. Body weight more systemic therapies including than 100 kg: initial dose 90 ciclosporin, methotrexate and mg SC, followed by 90 mg 4 photochemotherapy (PUVA). weeks later, & then every 12 weeks thereafter.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 299 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1614 Valganciclovir 450 mg J05AB14110T1001X For the prevention of For adult patients who have Tablet X A* cytomegalovirus (CMV) received other than kidney disease in CMV-negative transplant, the recommended Valproic Acid and Sodium N03AG01520T5001 B patients who have received a dose is 900 mg (two 450 mg1615 Valproate (ER) 500mg XX solid organ transplant from a tablets) once a day starting A/KK CMV-positive donor within 10 days of Tablet C09DA03935T1005X A/KK transplantation until 100 days X A/KK i) In the treatment of post-transplantation. For Valsartan 160 mg and generalized or partial adult patients who have1616 Hydrochlorothiazide 12.5 C09CA03000T1002X epilepsy, particularly with the received a kidney transplant, X following patterns of the recommended dose is mg Tablet seizures: absence, 900 mg (two 450 mg tablets) C09DA03935T1001X myoclonic, tonic-clonic, once a day starting within 101617 Valsartan 160 mg Tablet X atonic-mixed as well as, for days of transplantation until partial epilepsy: simple or 200 days post- Valsartan 80 mg and complex seizures, secondary transplantation.1618 Hydrochlorothiazide 12.5 generalized seizures, specific i) Adults: Dosage should start syndrome (West, Lennox- at 500mg daily increasing by mg Tablet Gastatut). 200mg at three-day intervals ii) Treatment and prevention until control is achieved. This of mania associated with is generally within the dosage bipolar disorders. range 1000mg to 2000mg per day. Children: >20KG: Treatment of essential 500mg/day (irrespective of hypertension weight) with spaced increases until control is Patients who cannot tolerate achieved. ACE inhibitors because of ii) Initial dose of 1000mg/day, cough, in to be increase rapidly as i) Hypertension possible to achieve lowest ii) Heart failure therapeutic dose, which iii) Post myocardial infarction produce desired clinical effects. Recommend initial Hypertension in patients who dose is 1000mg & 2000mg cannot tolerate ACE daily. Max dose 3000mg inhibitors because of cough daily. 1 tablet once daily i) 80 or 160 mg once daily. May be increased to 320 mg once daily. ii) 40 mg twice daily. Uptitration to 80 mg and 160 mg twice daily. Max: 320 mg in divided doses. iii) 20 mg twice daily. Uptitration to max of 160 mg twice daily. 1 tablet once dailyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 300 / 314